annual report innovate healthcarecover gudrun schindler knows important people diabetes able monitor blood glucose levels easily reliably type diabetes besides actively involved diabetes project gambia africa running diabetes selfhelp group past years years gudrun using accuchek systems roche diabetes management one many areas roches strong focus research produced pioneering innovations helped make group global market leader see also key figures key figures millions chf roche group continuing businessesa change change chf lc chf lc sales research development ebitdab operating profit exceptional items operating profit financial income net income exceptional itemsc net income epsdbefore exceptional items chf epsdin chf research development sales ebitda sales operating profit exceptional items sales effective tax rate net income sales roche group roche group december december net liquidity total assets equity minority interests debt equity ratioe debtequity ratiof continuing businesses includes pharmaceuticals diagnostics businesses treasury corporate activities consumer health otc vitamins fine chemicals reported discontinuing businesses b ebitda earnings exceptional items interest financial income tax depreciation amortisation including impairment corresponds operating profit exceptional items depreciation amortisation including impairment c net income exceptional items eps exceptional items calculated shown eps earnings per share nonvoting equity security diluted e equity ratio equity minority interests percentage total assets f debtequity ratio debt percentage equity including minority interests lc local currencies nonvoting equity security genussschein price performance chf roche nonvoting equity security adjusted swiss market index rebased brief sales grow significantly ahead market net income doubles group sales continuing businesses local currencies highest operating profit roche history net income doubled billion swiss francs substantial improvements equitytoassets ratio net liquidity board propose th consecutive dividend increase swiss francs per share nonvoting equity security pharmaceuticals division gains additional market share operating profit margin significantly market leadership oncology strengthened innovative anticancer medicines avastin tarceva receive first market approvals filings submitted bonivabonviva osteoporosis sixtyfour new molecular entities rd pipeline diagnostics sixth straight year market share gains significant improvement operating profit margin growth significantly market average key segments first dna chipbased test introduced support personalised therapy outlook pharmaceuticals diagnostics divisions expect continued market growth please visit httpwwwrochecom additional information roche operating profit margins exceptional items annual report innovative solutions spanning entire healthcare spectrum predisposition early detection prevention diagnosis therapy monitoring roche mission improve peoples health quality life leading researchdriven healthcare company roche develops produces markets inno vative highquality products services unmet medical needs capabilities diagnostics pharmaceuticals enable us innovate across entire health care spectrum identifying disease susceptibilities disease screening populations risk prevention diagnosis therapy treatment monitoring annual report table contents annual report letter chairman predispositionamplichip cyp test roche group group results outlook strategy pharmaceuticals results regions therapeutic areas early detectionamplicor hpv test research development rd pipeline diagnostics results regions business areas research development key product launches scheduled preventionpegasys board directors executive committee board directors executive committee corporate governance finance diagnosisserum work area roche group financial review roche group consolidated financial statements notes roche group consolidated financial statements report group auditors multiyear overview supplementary net income therapymabtherarituxan eps information roche securities roche holding ltd basel financial statements notes financial statements appropriation available earnings report statutory auditors monitoringaccuchek roche global market presence sustainability report published asa companion volume annual report annual report letter chairman franz bhumerchairman chiefexecutive officer outstanding year companywe carethe groups pharmaceuticals diagnostics achieved cases even exceeded businesses supply products spanning entire ambitious goals yearour operating profit healthcare spectrumfrom early detection highest ever roches historywe gained prevention disease diagnosis treatment marketing approvals two breakthrough anti two businesses excellent strategic fit cancer medicinesand intensified focus playing major role shaping core capabilitiesthanks strong oper future medicine contributing per ating performance gain sale ofour sonalised therapyfor examplegiven tremen consumer health business net income dous need new better medical solutions doubled reaching billion swiss francs explosive progress science technology annual general meeting ofshareholders board outlook continued growth good despite directors propose dividend increase todays challenging marketplace swiss francs per share nonvoting equity securityifapprovedthis groups last year roche divisions posted eighteenth consecutive dividend increase sales growth significantly market average improved profitabilityas resultcom following sale consumer health unit bined operating profit continuing businesses todays roche clearly positioned research exceptional items rose approximately driven company focused innovation health billion swiss francs annual report letter chairman reinforced leadership oncology expiries pharmaceuticals industry rocephin gained market share major therapeutic major roche drug go areas ofinterestincluding virology transplan patent united states tationas resultroche moved global successful moving every one rankings eighth largest pharma major research development projects forward ceutical company diagnostics business also expect adding even innova performed strongly sixth straight year tive medicines portfolio years ahead grew significantly faster market pharmaceuticals diagnostics pipelines extending market leadership today rank among best industrythanks strong financial commitment rd importantly future divisions area invest billion swiss francs scored major successes bringing innovative annually new products market advancing projects research development rd pipelines last year roche received prestigious prix galien tarcevawhich approved last year united nobel prizefor pharmaceutical innovation states medicine class pioneering new hivaids medicine fuzeon shown improve survival patients advanced cancers lung pancreasavastin roche together genentech chugai medicine offering completely new therapeutic world leader biotechnologyand area approach colorectal cancerreceived first mar intend become even strongerboth ket approval united states last february research development production end ofthe year generated nearly mil next several years example lion swiss francs sales never new invest billion swiss francs expanding biopharmaceutical adopted quickly groups biotech production capacity basel prescribersthe significance ofthese achievements switzerlandpenzberg germanyvacaville usa goes far beyond commercial impactfor utsunomiya japan give fresh hope patients cancerwhich still second leading cause ofdeath industri company afford high level expendi alised countries ture projects require take commercial risks involve unless solid financial addition gaining first market approvals footingour financial position improved substan two anticancer medicines received tially last yearthanks strong gross approval lymphoma treatment mabthera cash flow billion swiss francs rituxan hepatitis drug pegasys new indi core businessesgroup debt interest expenses cations means significantly larger declined significantly net liquidity doubled number patients eligible treat almost billion swiss francs ratio ment important productsin diag equity total assets reached nostics division launched first accuchek insulin pump stateoftheart device course solid financials alone enough benefit many people living diabetesand sustainable business success second launch amplichip cyp test europe year yearend reporting includes sus united states important step towards tainability report describes progress personalised medicinethis dna chipbased creating value environment economy test marks beginning new generation society respected us business magazine diagnostic tools identify clinically relevant recently included us first time list genetic variations thus help improve treatment best companies work united outcomes statesthis honour shared european companiesand one employees thanks many young products portfolio proud roche one lowest exposures patent annual report letter chairman last several years steadily strengthening corporate governance roche bruno gehrig serving board independent lead director since last years annual general meetingand recent changes struc ture corporate executive committee given us broader leadership base established clear deputising arrangements company today enjoys number ofsignificant competitive advantages well equipped continued successi wish thank youour share holdersfor confidence strategy roches management team would also like tothank employees valuable contribu tion making good year roche franz bhumer annual report medicines work differently sister sarah staehelin lives family binningenswitzerlandmetabolises certain medications moreslowly childrenthis means normaldose another child age could toxic predisposition early detection prevention diagnosis therapy monitoring annual report dna chips technology tremendous promise reason us respond differently doses medicines may lie genes experts estimate genetic factors account differences individuals metabolise respond drugs amplichip cyp test enables comprehensive analysis two genes play key role metabolism many widely prescribed drugs first dna chipbased test approved clinical diagnostic use test thus help predict basis patients genetic makeup whether metabolise certain medicines slowly normally quickly information assist doctors prescribing appropriate medication appropriate dose patients dna chips long since earned place disease research amplichip cyp test signals start new era clinical diagnostics chipbased tests help doctors tailor therapies patients individual genetic profiles predisposition genes influence effectiveness certain drugs also contribute risk developing disease advances human genetics promise give us new insights links genes disease understand links greater chances one day able use genebased tests better identify predispositions disease early knowl edge may help doctors patients take timely action delay possibly even prevent onset disease annual report roche group group results beforeand diagnostics division ebitda margin advanced percentage points sales revenues groups continuing busi groups net liquidity nearly doubled nesses rose billion swiss francs billion swiss francsthanks strong increase local currencies swiss positive cash flows divisionsthe sale ofthe francs results exclude consumer health consumer health otc businesses conver otc businesses vitamins fine sion ofthe lyons ivnotesthe ratio ofequity chemicals business sold total assets rose significantlyfrom roche divisionspharmaceuticals diagnostics grew significantly faster global market sale ofthe otc businesses roche chugai prescription drug sales advanced local resulted exceptional pretax gain totalling currencies swiss francs positive billion swiss francs contributions growth coming roche prescription subdivision local currencies group also completed major acquisition dur strategic alliances genentech ing yearpurchasing igen united states united states us dollars chugai early total consideration billion japan japanese yenin diagnostics swiss francs division sales rose local currencies swiss francs led divisions diabetes care financial income showed yearonyear molecular diagnostics immunochemistry busi improvement group recording net nesseswhich posted growth significantly financial expense million swiss francs market average compared expense million swiss francs group debt reduced operating profit continuing businesses billion swiss francs billion swiss substantially year advancing francs resulting decrease interest expense local currencies swiss francs nearly conditions thus place balanced billion swiss francs exceptional items financial income conversion operating profit margins divisions redemption debt instruments yielded excep increased sharply pharmaceuticals tional pretax gain million swiss francs division operating profit margin rose per including exceptional gain financial income centage points margin positive diagnostics division gained percentage points reach strong sales growth productivity net income increased billion swiss improvements gains realised dis francs billion swiss francs thanks fur posal noncore products technologies ther improvement groups operating results roche continued realign product portfolio gains sale otc businesses major contributors groups improved conversion redemption debt instru profitabilitytogether factors ments set increased costs new product launches investments groups rd pipeline expenditures inlicensing agreements prod outlook ucts technologies even excluding gains disposal products operating margin results pharmaceuticals division improved significantly influenced expiry ofthe us patent rocephin costs product launches key thanks strong operating performances ofthe markets significant development activitiesas groups continuing businessesebitda overall outcome anticipate localcurrency businesses billion swiss francs sales growth world market oper ebitda margin thepharmaceuticals divi ating profit margin exceptional items sion reached compared year broadly line annual report roche group roche diagnostics expects outgrow pharmaceuticals diagnostics divisions world market terms oflocalcurrency sales majority shareholdings genentech division also expects progress towards usa chugai japan backbone ofour goal ofan operating profit margin excep innovation network capabilities aug tional items ofaround mented technology collaborations constel lation alliances develop individual products addition roche expects balanced financial entire product portfolios decentralised income strategy enables us combine maximum scope flexibilitywhile also allowing partners necessary entrepreneurial freedom strategy pharmaceuticals group roche pharmaceuticals discoversdevelopsmanu scientific advances demographic trends eco factures markets clinically differentiated med nomic developments reshaping healthcare icines offering real added value existing treat healthcare industrythe explosion ofscientific ments efforts focused addressing unmet knowledge led disciplines genetics inadequately met medical needs selected genomics proteomics bioinformatics pro therapeutic areas particularly developing viding completely new insights human biology medicines help extend length diseaseopening way new approaches improve quality peoples liveswe aim diagnosis treatment good news since aleader ofour areas ofinterest still lack effective treatments ofthe dis eases afflict mankindto large extentof oncology good example ofthe strategic course coursedecisions resources set aside pursuing five anticancer medicines infrastructure provide healthcare shown improve patient survival public policy issues roche leader oncologya therapeutic area decades saw little progress despite roche recognises trends complex intensive global efforts cancer research one interplay continued process focus areas wide range restructuring roche group focus entirely promising projects rd pipelinevirology innovationdrivenhightech pharmaceuticals another key research area strong diagnostics businessesbecause exploit made important contributions enormous combined knowledge base example advancing treatment hepatitis businessesroche positioned play lead hivaidsroche also leader transplan ing role advancing new paradigms healthcare tation medicine anemia pipeline delivery tailormade products services delivering new products treat osteoporosis span entire healthcare spectrum asthma rheumatoid arthritis alzheimers disease emerging fields predisposition screening diabetes early detection prevention diagnosis therapy treatment monitoring broad scientific last year division invested billion swiss expertise areas helps patients andphysi francs research development figure cians make earlier better health treat clearly signals commitment remaining ment decisions comprehensive product sciencedriven company remarkable depth portfolio clear strategic advantage move quality rd pipeline widely recog steadily towards new era medical nised provides clear convincing evidence care increasingly tailored individual strong incompany capabilities patients productivity ofour partnering relationships annual report roche group biomarkers point way innovation research development better healthcare enoughto meet ambitious objectiveswe also pursuing technology leadership production areasbiotechnologyfor exampleis area steadily gained importance roche recent years already five roches ten top selling medicines manufactured using biotech nology combined revenues biopharma ceuticals currently account groups total prescription drug sales ability anticipate trends exploit potential new technologies long one roches strengthsour majority interest california based biotech pioneer genentech one biggest successful companies scientists roche pharmaceuticals roche industry dates way back diagnostics working together develop bio examplein additionwe one ofeuropes markers used diagnose diseases important biotech research manufacturing identify patients likely respond sitesin penzberg germany particular treatment help develop new drugs diagnostics biomarkers biological molecules provide diagnostic tools tests expected play genetic information metabolic disease increasingly important role ensuring processes tremendous potential diag patients correctly diagnosed early possible nostics search better medicines receive best available treatment thus helping optimise use oflimited healthcare roche biomarker program key part resources groups strategy linking pharmaceutical diag nostics expertise better targeted healthcare diagnostics industry thus vital contribu aim find biomarkers reveal presence tion make keeping medical care affordableon disease clinical signs symptoms appear averagelaboratory services account differentiate disease subtypes related total healthcare spendingyet informa conditions help identify patient subgroups differ tion services provide tremendous poten responses therapy provide leads tial making healthcare delivery whole potential drug targets biomarker tests improve efficient effective mean signifi ability diagnose disease open new pos cantly better costbenefit ratio sibilities prevention help developing expenditure roche diagnostics working today medicines safer work better turn potential gains reality help costeffective relieve pressure health budgets roche already markets tests tell doctors anti roche company supplying products viral treatment desired effect services segments invitro diagnostics patient tolerate certain medications market research institutions hospitals dosage groups combined expertise discover commercial laboratories patients novel ing developing novel diagnostic tests med analytical systems featuring powerful workflow icines puts forefront emerging field automation capabilitiesare cutting edge personalised medicine innovation laboratory technologyand con nectivity solutions data management systems examples stateoftheart products annual report roche group rocheby helping health professionals cope flood data increasingly complex teststhey contribute sounder therapeutic deci sionmaking increasing role patients managing health also farreaching implications diagnostics industryas role continues growso demand handyeasytouse instru ments match precision accuracy laboratory also make treatment recommendations mean trend towards actionable health information scientific research providing ever deeper insights causes diseasein addition enabling faster accurate diagnoses insights revealing ways identifying risk factors detecting presence ofdisease much earlier possible todaythis expand opportunities start preventive treatment measures stage onset ofdisease still avoided time understanding ofthe reasons medicines equally effective patients disease steadily increasing future dnabased tests help identify patients unlikely respond certain medicinescould adverse reactions could simply benefit dose adjustmentas resultphysicians able chose safermore effective options writing prescriptions patients developing medicines tests systems meet todays tomorrows needs requires extensive knowhow sizeable investmentsand roche prepared make investments highly focused healthcare company roche well equipped meet challenges ofa changing marketplace excellent position take advantage new opportunities growth combined knowhow diagnostics therapeu tics enables us create sustainable value patientsphysicians healthcare systems annual report greater certainty assessing cervical cancer risk cervical cancer second leading cause death cancer women almost always triggered certain forms human papillomavirus hpv seeing gynecologist regular screening tests helps detect hpv early tests available date clear limitations pap test alone often delivers inconclusive ambiguous results fails cases detect precancerous condi tions compared pap test amplicor hpv test new molecular diagnostic assay developed roche launched europe provides signifi cantly accurate indication risk one practical benefit healthy women may spared anxiety waiting results addi tional tests importantly means increased number patients may start receiving appropriate care early stage early diagnosis cervical cancer gives patients almost chance recovery early detection earlier disease detected better chances treating effectively screening examina tions increase likelihood spotting first signs disease providing timely therapy benefits targeted screening particularly evident respect highrisk groups since early diagnoses help patients also contribute controlling healthcare costs annual report available us hpv test important triaging abnormal pap smears screening warner khuh physician respected cancer researcher lives birmingham alabamausa valuesthe potential importance ofthe new amplicor test human papillomavirus hpv predisposition early detection prevention diagnosis therapy monitoring annual report pharmaceuticals division brief pharma executive committee since january william burns ceo division roche pharmaceuticals george abercrombie north america jennifer allerton informatics eduard holdener development peter hug partnering jonathan kc knowles research dominic moorhead finance controlling paul newtonsyms human resources charles sabbah strategic marketing claude schreiner western europe jan van koeveringe technical operations sales millions chf operating profit exceptional items millions chf number employees key figures change change millions chf chf local currencies sales sales roche prescription genentech prescription chugai prescription ebitda operating profit research development exceptional items annual report pharmaceuticals roche pharmaceuticals extended groups market leadership oncology helped outstanding clinical data products mabthera rituxan avastin tarceva launch avastin united states first market resounding success tarceva received first marketing approval united states late year drug class demonstrate survival benefit latestage lung cancer pan creatic cancer strong portfolio virology products also backed growing body solid data bringing benefits patients hepatitis hivaids influenza developments show successfully translating cuttingedge rd clinically differen tiated products also good business six prescription medicines exceed one billion swiss francs revenues william mburnsceo division roche pharmaceuticals annual report pharmaceuticals results sales region roche pharmaceuticals including genentech chugai continued deliver strong performance recording total sales million swiss francs represents increase latin america previous year local currencieswell ahead japan global market growth others driven groups oncologyvirology trans plantation franchises operating profit exceptional items increased advancing europe local currencies swiss francs north america million swiss francsdespite sustained high level investment rd product launch activities division posted another significant increase profitability recording operating profit margin exceptional items compared operating therapeutic areas margin also increased product outlicensing activities excluded ebitda oncology totalled million swiss francs salescompared previous yearthe cancer still one ofthe main causes ofdeath sale roches nonprescription medicines busi industrialised countries recent years seen ness bayer ofchugais otc business lion major treatment advances particularly promis corporation completed end ing approach targeted cancer therapy specifically attacks processes driving cancerous cells leaving healthy cells unharmed regions roche group forefront ofthis innovation regions contributed growth sales roche groups oncology portfolio roche genentech north america earned revenues billion swiss francs well ahead market fuelled pri posted gain oncology products marily strong demand avastin established account groups total prescription oncology brands hepatitis combination drug sales result strong perfor pegasys copegus oncology hepatitis mance expanded market share franchises also main contributors andconsolidated global lead important abovemarket growth europe vs therapeutic arearoche pharmaceuticals market averagesales chugai japan rose group offering five anticancer medicines compared local market growth ofin latin help extend lives cancer patients together america division recorded doubledigit sales unparalleled portfolio supportive care growth background steady market products improve quality oflife ofpeo recoverygrowth markets ofthe asiapacific ple cancer region strong middle east africa held well despite political economic turbulence growth rates based local currencies oncology portfolio mabtherarituxan herceptin avastin xeloda tarceva bondronat kytril furtulon neupogen neo recormon roferona neutrogin picibanil annual report pharmaceuticals biotech production therapeu nonhodgkins lymphoma nhl group malignancies lymphatic system affects tic proteins made order approximately million people worldwide claims estimated lives year mabtherarituxan worlds first therapeutic monoclonal antibody indolent aggressive forms nhl delivered strong growth particularly europe japansales ofthe prod uct benefited approval last august europe firstline use indolent nhlnew data show survival benefit group ofpatientsin addition two large clinical trials shown maintenance treatment mabtherarituxan two years highly effective patients indolent nhl biotechnology biopharmaceuticals led breast cancer common cancer among therapeutic breakthroughs number dis women worldwide herceptin monoclonal anti eases notably cancer roche forefront body targeted treatment breast canceris advances biotechnology aims tailored subgroup ofpatients particularly world leader biopharmaceutical rd produc aggressive type tumour herpositive tion marketing accounts approximately breast cancersin herceptin generated sales ofalmost roche group including genentech chugai billion swiss francswith solid gains major already owns almost third worlds biophar marketsadoption drug firstline therapy maceutical manufacturing capacity currently received major boost junewhen combina building new facilities basel switzerland penzberg tion herceptin plus taxotere approved germany vacaville usa utsunomiya japan indication european union clinical cost billion swiss francs new plants studies shown herceptin combination help build roches leadership biotechnology taxotere taxol significantly prolongs sur ensure sufficient manufacturing capacity vival ofpatients advanced breast cancerongo available meet expected demand groups ing clinical development aimed establishing new medicines thedrug combination hormonal treatment adjuvant therapy early breast cancer biotech manufacturing techniques harness natu ral biological processes living cells make use total sales ofxelodafor colorectal breast fulproducts products like innovative anticancer cer rose growth outside medicines avastin herceptin example united states impressive although sales biopharmaceuticals belong group ther growth united states impacted apeutic proteins known monoclonal antibodies first half year number important produced help cells genet changes marketplace prescription figures ically modified using recombinant dna techniques continued show increasing adoption ofthe prod cells cultured grown special fermenters uctglobal sales expected accelerate called bioreactors grow multiply helped new clinical datain august roche filed secrete desired protein antibody culture applications eu us authorities medium product harvested separating approval xeloda new indication adjuvant antibody biomass cells culture medium treatment colon cancer patients following waste products concentrated purified surgery taken orally xeloda far ready formulation final pharmaceutical convenient option patients product injectable regimens currently available annual report pharmaceuticals avastin shuts blood sales therapeutic area supply tumours transplantation dermatology metabolic disorders central nervous system infectious diseases cardiovascular diseases inflammatory diseases bone diseases virology others tumours like body tissues need con anemia stant supply oxygen nutrients get oncology creating network blood vessels process called angiogenesis avastin first medicine specifically inhibits tumour angiogenesis february genentech received approval avastin united states use combination targeting protein called vascular endothelial chemotherapy patients previously growth factor vegf key mediator tumour untreated metastatic cancer ofthe colon rectum angiogenesis avastin interferes blood supply extremely successful launch demand essential growth cancers product first market strong spread metastasis parts body resulting sales ofalmost million swiss francs less monthsin january avastin also although importance angiogenesis cancer received marketing approval euin decem growth long recognised wasnt ber avastin approved switzerlandwhich scientists genentech established vegfs criti also opens way registration medicine cal role promoting formation new blood ves countries worldwide guided sels tumours four years later demonstrated swiss regulatory decisions review pro specific antivegf antibody could suppress cessesclinical trials repeatedly demonstrated tumour growth opening way development avastinwhen added chemotherapysignifi avastin worlds first approved antiangiogenic cantly prolongs survival patients metastatic cancer treatment colorectal cancer regardless chemotherapy used data released november showed currently approved us eu switzerland product also significantly improves median israel combination chemotherapy patients survival patients relapsed metastatic colon metastatic cancer colon rectum avastin cancersee also research developmentp broad potential use number solid tumours groundbreaking new biopharmaceuti tarcevaa breakthrough anticancer drug developed cal testimony success roche genentechosi pharmaceuticals rochewas genentechs longstanding alliance approved us food drug administration fda november monotherapy advanced nonsmall cell lung cancer nsclc approval followed priority reviewwas based results phase iii trial showing drug annual report pharmaceuticals major product approvals launches product generic name indication country avastin bevacizumab firstline treatment combination chemotherapy usa metastatic colorectal cancer switzerland eu bonivabonviva ibandronate treatment prevention osteoporosis eu switzerland mg daily tablet herceptin trastuzumab metastatic breast cancer combination taxotere eu switzerland invirase saquinavir hiv disease mg formulation usa mabtherarituxan rituximab firstline treatment indolent nonhodgkins lymphoma eu switzerland neorecormon epoetin beta anemia indications iu prefilled syringe eu switzerland pegasys peginterferon alfaa hepatitis c prefilled syringe usa hepatitis b switzerland hepatitis c normal alt eu tarceva erlotinib second thirdline treatment advanced usa nonsmall cell lung cancer xenical orlistat prevention type diabetes xendos data eu usa includes supplemental indications updated end january extends overall survival patients pretreated ifleft untreatedthe global market antianemia lung canceran application marketing authori products currently estimated worth sation evaluated eu authorities billion swiss francs data another phase iii study showed tarceva increases survival patients background continued price pressure metastatic pancreatic cancer added anemia market whole roches neo chemotherapy tarceva currently investi recormon chugais epogin posted combined gated variety malignant diseases see sales billion swiss francs remain research developmentp leading products treatment ofrenal anemia respective marketssales neorecormon kytril used control nausea vomiting cancerrelated anemia grew driven patients receiving chemo radiation therapy successful launch penetration new undergone surgerycontinued perform onceweekly iu prefilled syringe offers well highly competitive marketplace patients high efficacy plus convenient dosing sales ofbondronat grew strongly helped transplantation continued rollout drug europe markets following approval prevention people worldwide receive lifesaving skeletal events patients breast cancer organ transplants yearthanks advances bone metastases surgical procedures immunosuppressive ther apy prevent organ rejection transplant recipi anemia ents survive many years new organswith longterm immunosuppressant treat anemia occurs number ofred blood cells ment routinedoctors reducing use falls normal starving organs tissues relatively toxic immunosuppressant drugs favour oxygen seen patients medications minimal toxicity impaired renal function due chronic kidney dis cellcept ease ofpatients cancerthe potential longterm effects anemia include car roche global market leader transplan diovascular disease renal patients reduced tation medicines groups transplan survival patients canceranemia fatal tation portfolio posted sales billion swiss annual report pharmaceuticals topselling products sales change product generic name indication millions chf local currencies mabtherarituxan rituximab nonhodgkins lymphoma neorecormon epogin epoetin beta anemia pegasys copegus peginterferon alfaa hepatitis b c ribavirin herceptin trastuzumab metastatic breast cancer cellcept mycophenolate mofetil transplantation rocephin ceftriaxone bacterial infections avastin bevacizumab metastatic colorectal cancer xenical orlistat weight loss weight control xeloda capecitabine colorectal breast cancer kytril granisetron nausea vomiting induced chemotherapy radiation therapy following surgery nutropin protropin somatropin somatrem growth hormone deficiency dilatrend carvedilol chronic heart failure hypertension coronary artery disease pulmozyme dornase alfadnase cystic fibrosis tamiflu oseltamivir treatment prevention influenza b cymevene valcyte ganciclovir cytomegalovirus infection valganciclovir neutrogin lenograstim neutropenia associated chemotherapy roaccutaneaccutane isotretinoin severe acne activase tnkase alteplase tenecteplase myocardial infarction madopar levodopa benserazide parkinsons disease jointly marketed roche genentech chugai marketed chugai jointly marketed roche chugai jointly marketed roche genentech francs increase roches flagship cytomegalovirus infection cmvvalcyte transplantation drug cellcept showing solid launched major markets new growthdespite entry new competitorsthe indicationthe prevention ofcmv disease solid products share total immunosuppressant organ transplant patients also remains market remains strong cellcept leading drug treatment cmv retinitis remains leading branded immunosuppressant hiv patients united stateswith total prescriptions us sales negatively impacted sec virology ond half year changes wholesaler buy ing patterns effects expected liver one bodys important disappear first half sales organs performing vital functions zenapaxused conjunction cellcept pre hepatitis b c viruses hbvhcv cause vent acute kidney transplant rejection increased acute chronic liver diseasepotentially leading million swiss francs liver failure cirrhosis cancer worldwide million people thought chronically combined sales valcyte cymevene showed infected hbv highly infectious pathogen solid growth valcyte became responsible estimated million deaths global market leader prevention annuallymore million people around annual report pharmaceuticals breakthrough hiv medicine world infected hcvand million new cases occur yearhepatitis c main reason tackles drug resistance liver transplantation roche enhanced leadership position hepatitis c sales combination therapy pegasys plus copegus advancing billion swiss francsat year end pegasys accounted ofboth us global pegylated interferon markets year new data demonstrated significant benefits pegasys plus copegus two hepatitis c patient subgroups patients co infected hiv patients persistently normal liver enzymes normal alt subgroup would traditionally considered treat ment roche received marketing authorisation developed jointly roche trimeris fuzeon europe normal alt indication novem first major innovation hiv treatment ber regulatory filings approval combi since novel mechanism action nation hivhcv coinfection submitted makes effective even strains mid european union virus resistant drugs united stateswe received apositive opinion eu authorities decemberand us filing drug resistance major challenge effective granted priority reviewroche com treatment hiv one study reports pleted development programme pegasys patients antiretroviral treatment north america chronic hepatitis bwith extensive clinical trial data infected strain virus resistant supporting use firstline treatment one antihiv drugs new medicines diseasemarketing applications filed combat drugresistant hiv thus urgently needed europe united states elsewhere january eu authorities recommended fuzeon helping address need first approvalfollowing approvals asiawhere hep new class drugs inhibit hiv replication atitis b particularly prevalentand december andits devastating effects immune system switzerlandpegasys become first pegy blocking virus enter human immune lated interferon indication anywhere cells treatment subcutaneous fuzeon signifi world cantly reduces viral load increases number healthy immune cells enhancing patient wellbeing hiv worldwide pandemic world health quality life advance hiv treatment organization estimates million people prestigious international prix galien pharma including million childrenwere living ceutical innovation hivaids end almost years roches innovative drugs diagnostic tests roche launched comprehensive nursetopatient placed forefront efforts combat patienttopatient support initiatives help hiv infection aids continue coach patients first three critical months working improve standard hiv care therapy time dramatic benefits worldwidefor information roches hivaids fuzeon seen selfinjection becomes rou initiatives see sustainability report visit tine wwwrochecom sales offuzeonfor treament ofhiv improved steadily reaching million swiss francs year end roche trimeris working annual report pharmaceuticals boniva makes osteoporosis accelerate uptake fuzeon major physician patient education initiativesstrong treatment easier take week treatment data presented yearconfirming virological immunological benefits good tolerability longterm treat ment fuzeonthese findings inclusion ofweek treatment data products us eu labels support case expanded use ofthe drugin fuzeon awarded prestigious international prix galien primary care global sales ofxenical slightly mar ket still overall declinewhile us sales fell significantly product experienced steady pharmaceutical innovation isnt find growth elsewhere september european ing new drugs also mean making effec commission approved removal kg pre tive drugs easier patients use treatment weightloss requirement disease involved common chronic products eu label based extensive longterm undertreated type innovation data supporting drugs efficacy safety widereaching benefits based results landmark xendos study us eu authorities approved label osteoporosis causes gradual loss bone density changes stating xenical delay onset making bones brittle prone break affects us reduce risk developing eu type millions people worldwide especially women diabetes obese patients menopause broken vertrebrae hips among potential consequences besides toll following patent expiries several major euro inflicts patients osteoporosis major impact pean markets april generic erosion led healthcare systems people break hip decline sales ofdilatrenda leading beta blocking example usually spend days hospital agent hypertension chronic heart failure coronary artery disease although cure osteoporosis treatment current bisphosphonates halt reverse due relatively mild influenza season sales bone loss reduce risk fractures however tamiflu declined despite initial orders ofpandemic using medicines complicated patients must readiness supplies preclinical tests shown take daily weekly tablet morning tamiflu effective highly patho empty stomach remain upright eat genic human avian hn influenza viruscon half hour currently around osteoporosis sidered likely source ofa pandemic strain patients stop therapy first six months thus experts called governments establish derive little benefit stockpiles tamiflu readiness possible pandemicroche working number ofgov bonivabonviva roches new bisphosphonate ernments determine requirementsit already first oncemonthly tablet osteoporosis increased tamiflu production capacity meet make much easier patients stay treatment additional demand plans increase thus minimising risk fractures patients unable tolerate oral bisphos phonates roche developing bonviva injections bonivabonviva developed first even people benefit innova oncemonthly oral treatment postmenopausal tive drug osteoporosisoneyear data twoyear multi annual report rd pipeline major development projects successfully brought forward therapeutic area projectid projectproduct generic name pharmacological class indication phase phase phase ii phase iii filed hematology r cera continuous erythropoietin receptor activator renal anemia nephrology r cera continuous erythropoietin receptor activator cancerrelated anemia genitourinary diseases r gpcr modulator stress urinary incontinence r gpcr agonist sexual dysfunction inflammatory autoimmune r mabtherarituxan rituximab anticd monoclonal antibody autoimmune diseases lupus nephritis bone diseases r mabtherarituxan rituximab anticd monoclonal antibody moderate severe rheumatoid arthritis r mabtherarituxan rituximab anticd monoclonal antibody refractory rheumatoid arthritis tnf nonresponders r integrin antagonist autoimmune diseases rheumatoid arthritis multiple sclerosis r kinase inhibitor rheumatoid arthritis r integrin antagonist inflammatory bowel disease r mra tocilizumab humanised antiil receptor mab systemic onset juvenile idiopathic arthritis r mra tocilizumab humanised antiil receptor mab rheumatoid arthritis r humanised anticd monoclonal antibody rheumatoid arthritis r bonivabonviva ibandronate bisphosphonate treatment prevention osteoporosis cardiovascular r enzyme inhibitor type diabetes metabolic diseases r nuclear receptor modulator type diabetes r enzyme modulator type diabetes r nuclear receptor modulator type diabetes r enzyme inhibitor type diabetes r nuclear receptor modulator dyslipidemia r xenical orlistat lipase inhibitor obesity development japan r xenical orlistat lipase inhibitor obesity label amendments r insulin sensitiser insulin sensitiser type diabetes r dyslipidemia r cetp inhibitor dyslipidemia neurological r gpcr modulator alzheimers disease psychiatric diseases r enzyme inhibitor alzheimers disease r pde inhibitor alzheimers disease r gpcr modulator depression r enzyme inhibitor alzheimers disease r pde inhibitor alzheimers disease r nk gpcr modulator depression anxiety r alzheimers disease r schizophrenia r anxiety oncology r mabtherarituxan rituximab anticd monoclonal antibody chronic lymphocytic leukemia st linerelapsed r mabtherarituxan rituximab anticd monoclonal antibody maintenance indolent nhl r omnitarg pertuzumab antiher monoclonal antibody solid tumours breast cancer lung cancer ovarian cancer prostate cancer r tarceva erlotinib egfr inhibitor nsclc ndrd line r tarceva erlotinib egfr inhibitor nsclc st line combination chemotherapy r tarceva erlotinib egfr inhibitor adjuvant nsclc r tarceva erlotinib egfr inhibitor pancreatic cancer r tarceva erlotinib egfr inhibitor glioblastoma multiforme r tarceva erlotinib egfr inhibitor nsclc nd line combination avastin r enzyme inhibitor solid tumours r enzyme inhibitor epothilone solid tumours r enzyme inhibitor solid tumours r monoclonal antibody metastatic breast cancer r enzyme inhibitor solid tumours r humanised anticd monoclonal antibody hematologic malignancies r enzyme inhibitor epothilone solid tumours r xeloda capecitabine fluoropyrimidine metastatic colon cancer st nd line combination treatment r xeloda capecitabine fluoropyrimidine adjuvant colon cancer combination treatment r xeloda capecitabine fluoropyrimidine adjuvant colon cancer monotherapy r xeloda capecitabine fluoropyrimidine adjuvant breast cancer r avastin bevacizumab antivegf monoclonal antibody metastatic colorectal cancer st line r avastin bevacizumab antivegf monoclonal antibody adjuvant colon cancer r avastin bevacizumab antivegf monoclonal antibody pancreatic cancer r ti b b tivegf l l tib l ir avastin bevacizumab antivegf monoclonal antibody renal cell carcinoma r avastin bevacizumab antivegf monoclonal antibody nsclc r avastin bevacizumab antivegf monoclonal antibody metastatic breast cancer r avastin bevacizumab antivegf monoclonal antibody ovarian cancer st linerefractory r enzyme inhibitor solid tumours r herceptin trastuzumab antiher monoclonal antibody adjuvant breast cancer r herceptin trastuzumab antiher monoclonal antibody metastatic breast cancer combination hormone therapy r herceptin trastuzumab antiher monoclonal antibody advanced gastric cancer r bondronat ibandronate bisphosphonate metastatic bone pain tumour types r solid tumours r oncology r oncology respiratory diseases r daclizumab anticd monoclonal antibody asthma r dual integrin antagonist asthma r nuclear receptor agonist emphysema viral r antibiotic bacterial infection infectious diseases r polymerase inhibitor hepatitis c r pegasys peginterferon alfaa chronic hepatitis b r invirase saquinavir protease inhibitor hiv mg tablet participation lucentis lucentis ranibizumab fab fragment antivegf agerelated macular degeneration genentech formerly amd fab xolair xolair omalizumab antiige antibody pediatric asthma peanut allergy participation bo antioxidant coronary heart disease chugai chs recombinant parathyroid hormone osteoporosis ed vitamin derivative osteoporosis cal antipthrp mab bone metastases chc polyglutamatetxl solid tumours ovarian cancer nsclc femara femara letrozole aromatase inhibitor breast cancer antevas antevas radical scavenger subarachnoid hemorrhage gm motilin agonist gastroparesis irritable bowel syndrome val liver regenerator post hepatectomy optin opportunities brfc fusion protein rheumatoid arthritis genentech r mabtherarituxan rituximab anticd monoclonal antibody multiple sclerosisanca associated vasculitis sle g topical hedgehog antagonist basal cell carcinoma pro apoltrail cancer vegf vegf recombinant vegf diabetic foot ulcers pro optin opportunities bal antifungal fungal infection r glp type diabetes r vascular targeting agent solid tumours r ef modulator solid tumours r calcineurin inhibitor acute renal transplant rejection r nonnucleoside reverse transcriptase inhibitor hiv external partners project id currently nmes pharmaceuticals divisions rd pipeline genentechbiogen idec kosan biosciences kos earlystage development phase entered phase clinical testing phase ii chugai protein design labs phase iii filed genentech pro sankyo cs projects entered phase moved phase phase ii phase iii glaxosmithkline novartis ophthalmics nippon shinyaku ns novartis tanox phase transition preclinical clinical development japan tobacco jtt biogen idec phase initial studies healthy volunteers possibly patients memory pharmaceuticals mem curis phase ii efficacy tolerability dosefinding studies patients memory pharmaceuticals mem amgen immunex phase iii largescale studies patients statistical confirmation ofsafety efficacy genentech basilea pharmaceutica bluetype signifies first indication blacktype additional indications genentechosi pharmaceuticals ipsen bim current december kosan biosciences kos antisoma dmxaa ipsen arqule arq therapeutic protein antisoma isotechnika small molecule ipsen bn medivirfoldout rd pipeline pharmaceuticals national study show oncemonthly oral boniva research projects major therapeutic areas effectivewelltolerated convenient alter dec native current daily weekly oral bisphospho nate regimens potential improve longterm treatment adherence addition new oncology data multinational study injectable neurological psychiatric diseases boniva shown first injectable bis phosphonate effective administered viral diseases every two three monthsoffering osteo respiratory diseases porosis patients greater choice especially help genitourinary diseases ing unable tolerate oral therapythe inflammatory autoimmune bone diseases monthly oral formulation already filed cardiovascular united statesthe european union switzer metabolic diseases land preparing launch together partner glaxosmithkline marketing application boniva twomonthly three monthly intravenous injection submitted us fda end aim develop wellprofiled medicines add major products significant value patientsphysicians payers ofour therapeutic areas ofinterestpharma rocephin remained worlds leading injectable research applying strategy steadily antibiotic posting total sales bil increasing quantity quality lion swiss francsrocephin strong year compounds moved development screening united states sales growing european undesirable characteristics sales ofthe product declined less expected due discovery stagepreclinical clinical riskdefin delayed introduction ofgenerics italy ing studies traditionally conducted later phases moved phase sales roaccutaneaccutanefor severe acnefell may result longer phase cycle times onethird decline believe increase quality ofthe compounds largely due market entry ofcompeting gener entering latermore costly development phases ics united states europe additionwe aligned drug safety evaluations roche worked closely eu health authori discovery right marketing ties introduction enhanced har seamless process monised pregnancy prevention programme women taking roaccutaneaccutane isotretinoin pharmaceuticals division rd pipeline cur member statesin united states roche rently includes new molecular entities nmes working fda generic manufac phase phase turers create register ofall patients treated phaseii eight phase iii filed products containing isotretinoin register expected launched july roche research development filed replace current accutane programme twelve investigational new drug applications fdaa significant increase previous years research development see foldout pipeline details regularly roche pharmaceuticals invested billion swiss updated information roches rd pipeline francs rd ofsalesthis please visit httpwwwrochecomhomeinvestors puts us industry average shows invpipelinehtm strong commitment innovation annual report pharmaceuticals roche rd expects advance least five projects major development activities phase ii clinical testing main growth area oncology roche rd increased oncology number projects twelve roche genentech pursuing comprehen end currently research pro sive clinical programme investigating use jects across seven therapeutic areas develop avastin number ofchemotherapeutic agents ment projects eight therapeutic areas advanced colorectal cancer adjuvant ther rochemanaged rd projectseleven termi apy following surgery avastins mechanism nated four phase four phase action may relevant number malignant two phase iionly one product pemtumomab tumourswe also investigating drugs poten terminated phase iii tial clinical benefit cancersincluding non small cell lung cancerpancreatic cancerrenal cell innovation network carcinoma breast cancerapproximately patients expected enrolled clinical trials roche pharmaceuticals continued worldwide next several years expand access innovative researchtechnolo gies compounds hubandspoke tarceva designed interfere molecular strategy combining strong inhouse rd signal stimulates tumour cell growth external partnerships alliances numerous types cancer currently investigated variety malignant diseases november roche strengthened global global alliance rochegenentechosi pharma research network opening new pharmaceutical ceuticals chugai tarceva also evalu rd centre shanghai china new facility ated combination avastin focus medicinal chemistry research lead generation optimisationcomplementing major programmes exploring role ofherceptin activities groups rd centres adjuvant breast cancer ofxeloda adju vant setting colon breast cancer continu roche genentech made important progress ingas exploratory trials potential coordination research activities agree benefits several earlystage molecules dis ment signed sets framework tinct mechanisms ofaction number ofcancers joint projectsfollowing review discovery portfolios oncology immunology roche scientists identified class small researchers evaluating potential molecules activate key tumour suppressor three joint projects pathway protects cells becoming malig nant new research could offer completely roche signed new research new strategy cancer therapy technology agreements nine product agree ments including important ones oncology hematology nephrology anemia arqule syrrx virology pharmasset structural development cera first continuous ery genomix vascular diseases japan tobacco thropoietin receptor activatorfor treatment year several alliances existing part renal cancerrelated anemia progressing ners including affymetrix anadys bioxell elan trackcera represents major advance anemia evotec memory norak expanded management recruitment global phase iii amended enhance valuein additionroche renal anemia studies advancing well phase sold rights tasmar valeant pharmaceuticals iii studies cancerrelated anemia due start rights soriatane united states midroche plans file marketing applica connetics tions united states elsewhere annual report pharmaceuticals rheumatoid arthritis asthma rheumatoid arthritis ra autoimmune dis r novel nonsteroidal oral treatment order characterised joint inflammation targets inflammatory process underlying even treated result progressive joint asthma results two phase ii studies showed destruction ultimately loss function r good safety tolerability profile cause unknown ra also shorten life based initial efficacy dataroche continuing expectancy affecting major organ systemsless development ofthe moleculewith phase iib stud ra patients able work per ies scheduled begin form everyday tasks ten years developing disordernearly six million people suffer ra roche protein design labs agreed worldwide codevelop daclizumab use asthma related respiratory conditions based positive phase ii roche genentech biogen idec developing study data patients moderate severe mabtherarituxan treatment ofrait asthma daclizumab currently approved first bcell depleting agent studied dis immunosuppressant transplant patients ease development progressing track brand name zenapax global filings initial indication patients inadequate response currently prescribed vascular diseases biologics planned second halfof roche licensed innovative cetp positive data phase ii study dancer inhibitorcurrently phase ii developmentfrom announced novemberin study patients japan tobacco addition potent moderate severe ra received two infusions highly selective ppara agonist licensed mabthera twoweek period combina nippon shinyaku phase development tion stable dose ofmethotrexate experienced molecules shown raise levels ofgood improved symptoms compared patients cholesterolor hdlcwhich may help prevent received placebo methotrexate coronary events targeted approaches seen new frontier cholesterol control development ofmra antiinterleukin recep tor antibody ra also progressing track november roche decode genetics phase iii studies ofthis novel biopharmaceutical announced formation ofa threeyear collabora ra commenced europe united states tion develop commercialise phosphodi end esterase pde inhibitors prevention treatment vascular disease including stroke diabetes new alliance expands scope collabora work continuing development insulin tion two companies beyond genetically sensitiser r treatment oftype diabetes driven target discovery activities next phase following new guidance fda data ofdrug research requirements class drugs r belongsroche decided wait results ongoing longterm toxicity studies starting phase iii clinical trialsthe toxicity studies completed first halfof rr r treatment oftype diabetes clinical development decisions entry phase ii expected please visit wwwrochecomhomedivisionshtm novel compounds represent next genera formore information roche pharmaceuticals tion oforal antidiabetic medicines annual report doctor told hcv would difficult treat thanks pegasys im virusfree monique wald lives daughter near frankfurt maingermanyshe probably became infected withhcv genotype early sbut diagnosed chronic hepatitis c predisposition early detection prevention diagnosis therapy monitoring annual report pegasys highly effective medicine forallhepatitis c virus genotypes hepatitis c major cause acute liver inflamma tion cancer left untreated cause chronic progressive liver damage leading cirrhosis buildup scar tissue liver ultimately liver failure death hepatitis c virus hcv properly identified cause hepatitis c unknown condition referred nona nonb hepatitis years virus hasmutated genetically distinct strains identified genotypes differ response treatment pegasys provides significant benefits patients hepatitis c matter viral genotype infected molecular structure pegylation allows therapeutic drug levels sustained full week one dose pegasys also dis tributed readily liver primary site infec tion pegylated interferon available readytoadminister solution clinical trials shown excellent treatment comes patients receiving pegasys combined copegus half patients infected genotype form hcv difficult treat achieved sustained virological response meaning virus could longer detected intheir blood prevention prevention involves identifying possible eliminating risk factors particular disease reducing minimum preventive treatment medicines interventions delay onset overt illness stop disease progressing limit serious organ tissue damage complications annual report diagnostics division brief diagnostics executive team since january heino von prondzynski ceo division roche diagnostics silvia ayyoubi human resources heiner dreismann molecular diagnostics staffan ek diabetes care christian hebich finance services tiffany olson market development volker pfahlert applied science burkhard piper centralized diagnostics jrgen schwiezer emea region europe middle east africa robert yates business development sales millions chf operating profit exceptional items millions chf number employees key figures change millions chf change chf local currencies sales sales diabetes care near patient testing centralized diagnostics molecular diagnostics applied science ebitda operating profit research development exceptional items annual report diagnostics successful year two reasons sixth straight year grew significantly faster market increased market share time improved operating profit margin novel technologies opening door new era diagnostics todays cuttingedge research genetics genomics proteomics make tomorrows diagnostic tests even accurate rapid efficient dna chips example help identify disease predispositions early stage paving way preventive action medium term contribute significant savings healthcare costs heino von prondzynskiceo division roche diagnostics annual report diagnostics results sales region roche diagnostics remained growth track sales advancing local currencies swiss francssales grew significantly faster market five ofthe divisions business areas europemiddle eastafrica led particularly strong gains diabetes care japan molecular diagnostics immunochemistry seg asiapacific mentsas resultthe division reinforced posi others tion global market leader north america iberialatin america profitability improved furtherthe divisions oper ating profit margin exceptional items reached ebitda margin climbed percentage points figures set new industry benchmarkoperating profit exceptional items increased million business areas swiss francswhile divisions ebitda rose million swiss francs diabetes care roche diabetes care remained leading pro regions viderofsolutions better diabetes management sales growing local currencies roche diagnostics outpaced market accuchek advantage accuchek regionsonce sales advanced doubledigit compact blood glucose meters among rates iberialatin america topselling products asiapacific region especially strong gains reported chinaindiakorea tai global diabetes market characterised wanthe division continued expand market rising cost pressures new treatment options leadership regions sales increased customer demands sophisti japanhelped success ofthe divisions cated powerful diabetes management systems diabetes careblood screening immunochem meet challengesroche diabetes care istry businesses adjusting sale expanded accuchek product family several product lines north american stateoftheart accuchek dtronplus insulin sales rose comparable basis increase pump first pump carry accuchek well market growth rate diabetes name launched also new accu management products molecular diagnostics chek pocket compass diabetes management immunochemistry biggest growth seg software package personal digital assistants ments europesales market region completes circle care allowing users includes middle east africa advanced record track data blood glucose yearand thus also grew significantly faster meter insulin pumpthis isthe first roche market product link blood glucose measurementanaly sis ofpatient data insulin delivery also saw launch accuchek multiclix worlds first lancing device use integrated lancet drummulticlix offers enhanced hygiene safety lancets automatically retract sixlancet drum immediately use annual report diagnostics topselling product lines sales change product line market segment business area millions chf local currencies accuchek diabetes management diabetes care cobas integra clinical chemistry centralized diagnostics roche hitachi elecsys immunochemistry centralized diagnostics amplicor tests clinical molecular molecular diagnostics cobas amplicor diagnostics cobas ampliscreen nucleic acidbased molecular diagnostics blood screening coaguchek coagulation monitoring near patient testing excluding hias homogeneous immunoassays division manufacturing blood glucose sales coagulation monitoring products seg meters china well production sites ment roche far largest market ineurope north americathe new production share grew demand facilitywhich operational since mid fuelled mainly continuing trend system strengthened roche diagnosticspresence atic anticoagulation managementmore highgrowth chinese market given division european health insurers begun reimbursing broader base compete successfully costs patient selfmonitoring far east wholein china alonethere benefits documented several interna currently million people living tional clinical trials selfmonitoring diabetesand figure projected increase five shownfor exampleto significantly reduce risk fold within next two tothree decades thrombosis patients artificial heart valves mid fda issued letter citing certain deficiencies manufacturing processes docu roche diagnostics also leader hospital mentation disetronicthe insulin pump manu pointofcare segment rapid testing products facturer acquired roche earlier year use hospitals accident scenesthe deci procedures processes question sion tighten focus core areas since modified conform roche positive impactas reflected good sales ofcardiac groups worldwide quality standards roche assays large increase new placements working closely fda officials preparation blood gas electrolyte analysersplacements pending fda reaudit ofthe burgdorfpro omni multifunctional blood gas analysers duction site switzerland following successful exampleshowed fourfold increase completion reaudit roche move quickly start sales newgeneration insulin global rollout urisys successfully pumps united states completed compact system stan dardised urinalysis designed use doctors near patient testing offices small laboratories roche near patient testing leading supplier centralized diagnostics products services rapid diagnosis pointofcare settingsfrom ambulances inten roche centralized diagnostics leading supplier sive care units doctors offices patients integrated total solutions clinical laborato homessales business area grew local riesreported abovemarket sales growth currencies local currencies annual report diagnostics mounting pressure contain medical costs licensing marker hscrp high sensitivity make healthcare delivery efficientcombined creactive protein used assess cardiovascular shortages ofskilled laboratory staffis fuelling riskhscrp third important cardiac marker demand costeffective fully automated inte divisions portfolio already includes grated laboratory systems biomarkers tests heart attack heart failure modular analytics swa serum work areas another segment roche leader molecular diagnostics meets needs oftodays laboratory marketcom bining clinical chemistry immunochemistry roche molecular diagnostics remains undis testing single platform system one puted market leader highgrowth segment centralized diagnosticskey growth drivers sales diagnostic products local currencieswhile sales ofenzymes industrial cus performance business area largely driven tomerswhich account smaller percentage strong rise immunochemistry saleswith revenuesshowed gain ofblood screening acquisition igen providing important addi womens health products main growth tional stimulus growthcompleted february drivers strategic transaction secures roches rights electrochemiluminescence ecl sales blood screening segment advanced technology underlying elecsys line ofimmuno impressive viral tests used chemistry productsfrom prod screen units blood worldwide uct line consistently achieved sales growth nucleic acidbased testing system new placements elecsys systems look viruses directlyrather anti reached record highand sales rose another bodies formed response infection tests medium term roche diagnostics aims based nucleic acid technology nat help become leader immunochemistrya growth ensure availability safer blood blood market currently valued billion swiss francs products sooner new tenyear agreement longstanding saw signing three major agreements japanese partner hitachi hightechnologies areaone ofthe agreements extends exclu brought us another step closer achieving sive contract japanese red cross goal roche hitachi continue develop additional four years another provides automated laboratory solutions set new stan korean red cross use roche tests screen dards innovationjust done blood donationsthe third agreement past years german red cross marks roches entry german blood screening market division also continues invest technolo realtime pcr instrumentsthese instruments gies automate many steps precede based secondgeneration pcr polymerase follow actual testing laboratoryfor example chain reaction technology pcr technology roche diagnostics extended cooperation copy dna fragments sample millions oftimes agreement preanalytical systems pvt enabling detection even minute probenverteiltechnik germanya move rein amounts ofbacteria viruses forces divisions lead supplier oftotal labo ratory solutions addition application clearance cobasampliscreen hbv test screening donor cardiovascular testing segmentcentralized bloodfor hepatitis b virus submitted diagnostics increased availability nt fda probnp key marker heart failure outlicensing agreements last year also filings also submitted fda expanded product portfolio expanded indications cobas ampliscreen annual report diagnostics gender matters hiv hcv products nat testing cadav eric fluid hiv hepatitis c virusclearance products indications help increase safety oforgan tissue donations division added another important test womens health portfolio successful european rollout amplicor hpv test capable identifying clinically relevant human papillomavirus hpv genotypes hpv infection recognised leading cause cervical cancerfrance first european country approve reimbursement testwe expect hpv tests significant positive impact diagnosis treatment cervical cancer awareness significant health dif see also research developmentp ferences men women nothing new wasnt recently researchers tests chlamydial infections gonorrhea began systematically investigating differ among common sexually trans ences findings sometimes startling mitted diseasesposted doubledigit sales growth example recent studies shown risk roche molecular diagnostics maintained arteriosclerosis increases dramatically women leading position fiercely competitive virol following hormone changes occur ogy market business areas quantitative test menopause contrary widespread belief hepatitis b qualitative test hepatitis c heart disease claims lives women two major growth driversin addition men besides susceptible genderspe hepatitis c genotyping test made available cific diseases like breast cancer still leading forresearch use united states cause death women aged women frequently victims sexually transmitted sales genomics segment showed double diseases men infertility common complica digit growth strong gain due part tion chlamydia infection cervical cancer amplichip cyp test worlds first micro usually preceded infection human arraybased test clinical diagnostic use papillomavirus hpv launched year europesince jan uary also cleared marketing good reasons devoting even united statesthis novel test provides valuable research womens health though area information assessing bodys ability means new roche diagnostics metabolise medications vary greatly worlds broadest portfolio womens health tests individualsit one new generation including tests osteoporosis fertility diagnostic tests identify clinically relevant infectious diseases new hpv test illustrates genetic differencesthus helping physicians select roche relying heavily modern molecular tech appropriate drugs dosages nologies hope set new standards patients early detection treatment breast cancer ovarian cancer diseases applied science roche applied science supplier ofreagents hightech systems scientific industrial research major focus areas genomics proteomics following weak business annual report diagnostics dna chips tiny hightech achieved excellent growth sales rose wonders big future local currencies growth led sales lightcycler reagents applied sciences industrial business major contribution coming new placements oflightcycler instru ments placements dna amplification system continue increase steadily particularly inhighgrowth markets asiapacific region research development roche diagnostics invested million swiss francs research developmentsignifi cantly competitor division dna chips already established tool laying foundation future success concen research tiny devices conquering trating research efforts primarily three new worlds help doctors deliver fastestgrowing segments molecular diagnostics personalised healthcare based insights diabetes immunochemistry small important genomic differences diabetes care dna chips also known gene chips micro arrays thumbnailsized chips embedded main focus developing accuchek sys thousands precisely arranged dna fragments tems offering optimum userfriendliness one like molecular magnet attract one designed make living diabetes easierfor specific dna sequence sample every target start means providing patients systems sequence present sample react hybridise analyse data glucose monitor complementary fragment chip pro insulin pump turn data actionable ducing fluorescent dot visualised using information patients doctorsand special laser equipment resulting pattern also means developing stateoftheart insulin help identify genomic differences affect indi pumps like accuchek spirit scheduled vidual response treatment using results launch enable patients amplichip cyp test example doctors match insulin doses much closely better assess quickly patients metabolise individual needs certain drugs selecting drug dose additionprojects way develop inte dna chips able analyse huge numbers grated systems combine glucose measure genes simultaneously reason already ment data management insulin delivery play indispensable role research division working miniaturised device bright future many areas clinical diagnostic components minimally invasive technologies testing well eg distinguishing different continuous blood glucose monitoring systems cers viral infections genetic signatures treatment tailored precisely aim design pumps come close patients disease possible mimicking natural pattern ofinsulin release healthy individuals ultimately develop artificial pancreas deoxyribonucleic acid dna material carries genetic information annual report diagnostics major product launches business area product diabetes care accuchek dtronplus first insulin pump accuchek brand accuchek go blood glucose monitoring system capillary fill safety features accuchek multiclix multiple lancing system integrated lancet drum accuchek pocket compass diabetes management software accuchek safe tpro plus disposable lancing device adjustable depth setting accuchek spirit flexible menudriven insulin pump ce near patient testing datacare pointofcare data management software update v omni bloodgaselectrolyte combianalyser family expansion centralized diagnostics elecsys afp updated reagent assessment germ cell tumours elecsys cpeptide assay measuring cpeptide human serum plasma urine elecsys ferritin ii updated reagent assessment iron metabolism elecsys hiv combi combined hiv antigen antibody assay elecsys pnp bone formation marker treatment monitoring osteoporosis elecsys pth updated reagent assessment parathyroid function elecsys treatment monitoring skin cancer sta cephascreen coagulation test urisys urinalysis system molecular diagnostics amplichip cyp test microarray drug metabolism ce ivd amplicor hpv test test kit microwell plate format qualitative determination human papillomavirus ce ivd lineararray hcv test test hepatitis c virus genotyping research use ivd clinical use ce european ce mark certification conformit europenne near patient testing instrument connectivitythe cobas mod ular serum work area platform first new trend towards decentralised testing diagnostic generation analysers currently devel testing outside laboratory continue one oped specifically mediumthroughput labora mediumterm goal roche near patient testing tories supply portable devices capable ofperforming every important coagulation test business centralized diagnostics also investing area adding new products portfolio development ofnew immunoassaysresearch work cardiac marker tests including ntprobnp proteins already produced encouraging assay cardiac reader systemthis assay preliminary data new breast cancer markersand valuable tool ruling heart failure markers diseases including colorectal point ofcare cancer rheumatoid arthritis cardiovascular conditionsare also investigated centralized diagnostics molecular diagnostics roche centralized diagnostics working develop even costeffective total laboratory first quarter roche expects receive solutions focus workflow automation european ce mark certification lineararray annual report diagnostics key product launches scheduled business area product diabetes care accuchek aviva highend successor advantagesensor blood glucose monitoring system accuchek compact plus blood glucose monitoring system onestep handling integrated strip lancing devices accuchek pocket compass diabetes management software accuchek spirit flexible menudriven insulin pump usa near patient testing cardiac probnp test strip use cardiac reader diagnosis monitoring ofchronic heart failure cobas hospital pointofcare data management software centralized diagnostics cholinesterase assay assessment liver function available liquid reagent mpa mycophenolic acid new product monitor roche immunosuppressive drug elecsys prolactin ii optimisation macroprolactin detection elecsys vitamin new product extension bone marker portfolio ecl platform x dedicated hbac glycated hemoglobin analyser basis cobas integra molecular diagnostics amplichip cyp test microarray drug metabolism us ivd amplichip leukemia test detection different subtypes research use cobas ampliprep cobas taqman integrated systems sample preparation anddnarna analysis hiv hcv hbv cobas ampliscreen hbv test detection hcv hiv rna hbv dna inhuman plasma us ivd cobas taqman ct test detection chlamydiace ivd lightcycler factor v test detection mutations clotting factor v leiden ce ivd lineararray hcv test hepatitis c virus genotyping ce ivd lineararray hpv test human papillomavirus ce ivd sepsis test detection bacterial fungal dna whole blood ce ivd applied science htc system highend realtime pcr system throughput wells lightcycler cesw ivd version lightcycler dna amplification system quant pcr master taqman generic pcr master mix use common well real time pcr instruments ivd clinical use ce european ce mark certification conformit europenne hpv test identify hpv genotypes meet evergrowing demand blood test available research use blood products laboratories frequently screen united states pooled samples multiple donors saves time money also increases risk roche molecular diagnostics also currently plan thata virus may go undetectedtwo roche instru ning launch rapid sensitive chlamydia ments designed address safety issue cur assay cobas taqman instrument real rently development scheduled launch time pcrthis assaywhich already available outside united states blood screening amplicor instrumentwill major addition system blood screening system taqman menu since chlamydia assays dedicated fully automated instruments among nucleic acidbased tests frequently make possible screen individual samples performed molecular diagnostic laboratories quickly reliably costeffectively systems annual report diagnostics already met great enthusiasm interna tional blood service conferences moreoverroche molecular diagnostics develop ing clinical diagnostic tests use amplichip pcr technology based latest advances genomicshere roche working affymetrix usa decode genetics iceland discover additional genetic variations mark ers could useful development ofnovel tests particularly complex diseases like leu kemia collaboration agreement epigeno mics germany already yielding resultsin epigenomics identified number markers could one day facilitate early detection ofbreast colorectal cancers next step develop tests biomarkers applied science business area develops innovative reagents systems research life sciencesparticularly genomics proteomics product portfolio genomics expanded launch htc high throughput cycler system realtime pcr analyser feature higher sample throughput capabilities broad menu tests innovative tests identifying genetic variants scheduled launch please visit wwwrochecomhomedivisionshtm information roche diagnostics annual report tailormade solutions different kinds laboratories time essence nowhere truer clinical laboratories huge numbers blood serum urine samples processed every day large laboratories may perform tests hour understandably laboratories turning automated integrated solutions save precious timethat laboratories also want maximum cost efficiency insist absolute system reliabil ity goes without saying modular highthroughput analyser modular ana lytics swa serum work area delivers counts combining clinical chemistry immunoassay capabilities single platform system allows users consolidate scores tests blood chemistries like cholesterol electrolytes proteins hormones biomarkers eg cancer osteoporosis cardiovascular infectious diseases result samples processed single pass samples loaded automatically transferred one test position system next improves workflow efficiency also helps reduce labour costs system modular name says configured meet laboratories individual needs diagnosis cope todays broad range tests high sample workloads laboratories require systems combine high sensitivity precision speed userfriendliness critical providing physi cians fast accurate diagnostic information need treat patients early targeted diag nostic testing together tests monitoring dis ease progression treatment response one keys achieving successful treatment outcomes annual report fast accurate test results critical effective care laboratory physician imme mautewho lives berlingermanyprovides communitybased practitioners vital information decisions patient carein businessefficientreliable systems must predisposition early detection prevention diagnosis therapy monitoring annual report board directors executive committee board directors executive committee annual general meeting april richard laube head roche consumer bruno gehrig lodewijk jr de vink healthwhich sold bayerstepped elected new members ofthe board ofdirectors executive committee end date board appointed mr gehrig sale closed december suc vicechairman independent lead director cessfully led groups otc business since named chair boards remunera appointed executive committee tioncommitteemr de vink appointed board ofdirectors would like take finance investment committee opportunity thank mr laube significant contribution company wishes every current board terms ofjohn bellandr hoff success future endeavours mann franz b humer end next annual general meetingon february end board directors voted three gentlemen agreed stand reelec tointroduce number ofstructural personnel tion boardif reelectedchairman changes expand strengthen executive ofthe board franz bhumer continue committee changes became effective director also serving executive capacity january include appointment rocheand majority seats board william mburnswho heads groups pharma held independent directors ceuticals division ceo division roche phar maceuticals appointment heino von prondzynskihead diagnostics divisionas ceo division roche diagnostics chief financial officer erich hunziker appointed deputy head ofthe executive committee addition following key senior managers havebeen appointed permanent participants executive committeeeduard holdenerhead global pharma development peter hughead pharma partnering staffan ek head roche diabetes careand rolfschlpferhead ofcorpo rate communications osamu nagayama presi dent ceo ofchugaiwho participat ing meetings executive committee since requiredhas also named permanent participant completing medical studieseduard hold ener swiss worked internist annual report board directors executive committee board ofdirectors january left john bellrolfhnggipeter brabeckletmathe bruno gehrigandr hoffmannfranz bhumerlodewijk jrde vinkdeanne juliuswalter frey andreas oerihorst teltschik name year birth term ends first election board directors dr franz b humer f chairman prof dr bruno gehrig c e vicechairman independent lead director rolf hnggi b e vicechairman prof dr john bell c e peter brabeckletmathe e lodewijk jr de vink e walter frey b e andr hoffmann c e dr deanne julius b e dr andreas oeri b e prof dr horst teltschik e secretary board directors dr gottlieb keller finance investment committee january b audit corporate governance committee c remuneration committee presidiumnomination committee e nonexecutive member f executive member committee chairman annual report board directors executive committee oncologist several hospitals switzerland earning degree economicsrolfschlpfer clinical research university kansas swissheld several management positions theunited stateshe joined group marketing communicationshe partner member oncology group roches clinical managing director consultancy firm research organisation appointed head wirz identity joining roche head group mr holdener charge corporate communications includes pharma development roche japan internal external communications public appointment head global pharma affairs development recent years group steadily pursued peter hug also swiss phd eco strategy reshaping innovative nomics joined roche working first healthcare company focused pharmaceuticals variety positions pharma marketing diagnostics businessesand changes switzerland canada greece later gen executive committee mark another step eral manager groups affiliates uruguay direction new structure gives us broader switzerland spain career roche also leadership base clearly defined deputising includes two years head roches diagnostics arrangements enhances transparency func business germany september mr hug tions vital strategy ofinnovation assumed current position head pharma directly represented executive commit partneringwhere responsible groups tee important business areas strategically vital network collaborations corporate departmentsthis move help ensure alliances groups continued ability revitalise strengthen management team moreover staffan ekwho swedish degree busi new structure allow chairman ceo franz ness administrationbegan career market bhumer focus even strongly role ing consultant joining pharmacia phar chairman ofthe board ofdirectors maceuticals group worked years appointed head diabetes care unit boehringer mannheim german diagnostics company acquired roche ashead roche diabetes carehe manages business area accounting largest share ofroche diagnosticssales annual report board directors executive committee executive committee january left jonathan kcknowlesheino von prondzynski william mburnsfranz bhumererich hunzikergottlieb akeller name year birth position executive committee dr franz b humer chief executive officer dr erich hunziker chief financial officer william burns ceo divisionroche pharmaceuticals heino von prondzynski ceo division roche diagnostics prof jonathan kc knowles research dr gottlieb keller corporate services human resources permanent participants dr eduard holdener global pharma development dr peter hug pharma partnering staffan ek diabetes care rolf schlpfer corporate communications osamu nagayama president ceo chugai secretary pierre jaccoud executive committee statutory auditors kpmg klynveld peat marwick goerdeler sa since roche holding ltd principal auditor john morris since group auditors compliance officer dr andreas greuter direct phone number deputy head executive committee january annual report beaten cancer really treatment received mabthera adam morris data manager former professional soccer player lives newtownwales diagnosed nonhodgkins lymphoma ofthe bonea aggressive type ofcancerin predisposition early detection prevention diagnosis therapy monitoring annual report mabtherarituxan smart drug lymphoma nonhodgkins lymphoma nhl common cancer lymphatic system results defective production white blood cells mabthera marketed rituxan united states canada japan therapeutic antibody binds particular protein surface normal malignant b cells type white blood cell recruits bodys natural defences attack kill marked cells immune system work healthy new b cells produced thebone marrow treatment return mal levels within several months combination mabthera chemotherapy first new treat ment years improves survival patients aggressive nhl date patients around world treated mabthera therapy clinically differentiated medicines alone com bined interventions essential com ponent effective treatment many diseases diagnostic tests help physicians choose appropriate drug dosage monitor pa tients responses medication also playing increasingly important role therapy using together physicians tailor treatment patients individual needs improving clinical outcomes costefficiency annual report corporate governance corporate governance roche takes account organisational structure board principles govern management directors supervision company system checks balances ensures accountabilityin addition roches board directors organised complying existing legal internal ensure groups businesses conducted company regulations roche also operates responsibly focus longterm value accordance requirements set creation therefore years ago board companys articles incorporation bylaws directors roche holding ltd delegated certain roche meets requirements swx swiss responsibilities several committeesthese com exchange swx corporate governance directive mittees including commentary also subscribes presidium ofthe board ofdirectors swiss code best practice corporate nomination committee governance promulgated business federa chairmanfranz bhumer tion economiesuisse aim serve diverse audit corporate governance committee interests stakeholders particular chairmandeanne julius employees shareholders holders roche non finance investment committee voting equity securities customers bal chairmanrolfhnggi anced fashionthis commitment isreflected remuneration committee operating businesses focus innovation chairmanbruno gehrig value creation management culture characterised modernappropriate standards committees except presidium chaired ofcorporate governance independent directors combine printed annual report key bylaws board directors containing links roche website wwwrochecom details internal structure board enabling readers gain snapshot allocation authority responsibilities reporting date uptodate overview mandates board committees infor companys key corporate governance information mation control mechanisms available annual report contains information board dealings corporate management available december given yearwhile published internet internet provides source permanent constantly updated information companys articles bylaws articles incorporationthe bylaws cur board directors independent lead ricula vitae members board direc director may request member tors executive committee regularly convene board meeting without attendance updated made available internet chairman roche board meets require information year assess chairmans performance meeting held absence httpwwwrochecomhomecompany chairman chaired independent lead comgovcomgovbylawshtm director annual report corporate governance remuneration remuneration paid pro rata board membership period january march remuneration members board ofdirectors members board directors otherwiseno additional remuneration paid received remuneration shown table members ofthe board ofdirectors serving board remuneration members board directors special additional compensation remuneration remuneration committee members chf chf chf fb humer b gehrig r hnggi j bell p brabeckletmathe ljr de vink w frey hoffmann da julius oeri h teltschik total per committee membershipyear excluding members presidium vicechairmen chf remuneration paid chairman board fb humer executive member board directors deducted agreed salary see remuneration members executive committee remuneration serving independent lead director vicechairman pro rata period april december remuneration serving vicechairman board pro rata period april december special remuneration additional time required da julius evaluate new auditors remuneration special remuneration addi remuneration members executive tional compensation paid nonexecutive mem committee bers board directors serving members executive committee aforementioned capacities totalled swiss received salaries bonuses stock options francs nonvoting equity securities shown tables headed remuneration members execu nonexecutive members ofthe board ofdirec tive committee tors awarded shares options december held unvested senior managers members executive options awarded previous years committee additionally receive annual expense allowances swiss francs addition three nonexecutive members respectivelythechiefexecutive officer receives board directors stepped annual expense allowance swiss francsin received remuneration totalling swiss francs members executive committee annual report corporate governance remuneration members executive committee cash payments chf annual salary annual salary annual salary bonus bonus bonus fb humer wm burns e hunziker ga keller jkc knowles rt laube h von prondzynski total pro rata period october december b stock options nonvoting equity securities nes genussscheine total remuneration pspvalue total nesawarded per year remuneration threeyear psp programme cash stock stock options stock options stock options years ie options per year psp value chf value chf value chf total number chf value chf fb humer wm burns e hunziker ga keller jkc knowles rt laube h von prondzynski total blackscholes valuation described section c stock options pro rata period october december total received expense allowances totalling one roche nonvoting equity security nes swiss francs genussscheinunder terms well estab lished option planthe exercise price ofthe options richard tlaube stepped executive shown closing price roche nes committee december leave trading day prior roche annual media con company june richard laube ferenceall ofthe options shown nontradable awarded special bonus million swiss francs one third options subject vesting recognition successful completion period one yearone third vesting period sale ofroche consumer health rch oftwo yearsand one third vesting period ofthree years unvested options lapse without compensa c stock options tion member voluntarily leaves company december members ofthe executive vested options must exercised within committee held options shown table limited period oftimeifthey tradablethe fair stock optionsall options shown value ofthe options would calculated date table issued roche employee stock issue based blackscholes formula optionseach option entitles holder purchase deducting average twoyear vest annual report corporate governance stock options number options number options number options fb humer wm burns e hunziker ga keller jkc knowles rt laube h von prondzynski total exercise price chf expiry date allotment value per option chf value based blackscholes valuation minus pro rata period october december ing period exercise price expiry date roche connecta voluntary stock purchase allotment price shown table stock planemployees opportunity buy roche optionsabovethe value ofthe options table nonvoting equity securities nes genussscheine remuneration ofmembers ofthe executive com amount equal annual mitteebstock optionsnonvoting equity securi salary discountnes purchased ties nes genussscheine total remuneration plan subject holding period based calculation method used switzerland four years time ofissue performance share plan indirect benefits members executive committee employer contributions made members senior management whose social security schemes pension plans performance major impact roches ability groupwide employee stock purchase plan roche achieve corporate objectives indi connect respect members executive viduals worldwide participated perfor committee shown table indirect benefits mance share plan pspwhich established indirect benefits pension fundsmgb ahvivalv roche connect chf chf chf fb humer wm burns e hunziker ga keller jkc knowles rt laube h von prondzynski total mgb stiftung der f hoffmannla roche ag fr mitarbeitergewinnbeteiligung employee profitsharing foundation supplementing occupational pension benefits ahvivalv swiss social security programmes providing retirement disability unemployment benefits annual report corporate governance beginning provisions swiss francsthe distribution ofdividends totalled programme based salaries billion swiss francs nes price applied time number nes reserved participantsthe actual comparisonthe average total shareholder return distribution securities depended whether tsr peer set significantly lower andtowhat extent investment roche securi resulting decline value thus tsr ties shares nes outperformed average roche securities last three years return investments securities issued peer higher average tsr ofthe peer com setof companies operating indus panies try three years programme effect performance evaluated roche already made necessary provisions basis ofmarket price dividend yields psp pro rata basis annual accounts last three years roche securities shares nes including dividend yields consis psp ended december andin accor tently outperformed average return delivered dance provisions ofthis programmepar peer pharmaceuticals diagnostics compa ticipating executives vested double nies roche ranked second end number nes recognition contribu time roches market value increased tion companys success addition billion swiss francs billion swiss participants elected place percentage francsequivalent growth billion nes blocked account aperiod offour years detailed information concerning members executive committee presented table remuneration ofmembers ofthe executive com mitteebstock optionsnonvoting equity securi ties nes genussscheine total remuneration annual report peer set abbott laboratories amgen astrazeneca aventis bayer becton dickinson bristolmyers squibb eli lilly glaxosmithkline johnson johnson merck novartis pfizer sanofisynthlabo scheringplough takeda wyeth roche performance roche peer group average performance total shareholder return tsr value chf invested st week january roche market capitalisation billions chf roche securities chf nonvoting equity security nes share prices translated constant chf exchange rates tsr stock price change plus dividendcorporate governance remuneration emoluments loans note roche group consolidated financial corporate officers statements related parties gottlieb keller taken mortgage loan notes financial statements ofroche holding swiss francs pension fund ltd additionas december f hoffmannla roche ltd interest rate nonexecutive members ofthe board ofdirec pathe interest rate loan fixed tors persons closely associated held december sharesthe members ofthe executive com mittee persons closely associated pensions totalling swiss francs paid held shares date nine former executive committee members widows bonuses totalling relationship group auditors statutory swiss francs paid two former auditors executive committee members previous year annual general meeting roche holding ltd april kpmg klynveld peat marwick otherwiseno additional remuneration paid goerdeler sa kpmg elected group audi current former members executive com tors statutory auditors information mittee appointment group auditors date principal auditor took office highest total remuneration found group auditors chairman board ceo franz b statutory auditors participate audit cor humer member ofthe board mem porate governance committee meetingsthe audi ber executive committee highest tors make written oral reports results total remuneration shown tables auditsthe audit corporate governance aboveincluding allocation ofthe awards committee oversees assesses auditors threeyear performance share plan direct makes recommendations board infor salary follows mation responsibilities audit highest total remuneration chf cash payment stock options value based blackscholes formula minus performance share plan allocation per year total value shareholdings corporate governance committeesee article bylaws group auditors statutory directors andr hoffmann andreas oeri auditors participated three meetings ofthe audit members founders family corporate governance committee closely associated belong share holder group pooled voting rightsat end kpmg received following remuneration group held shares services group auditors statutory issued shares following fritz gerbers retire auditors roche holding ltd roche ment board departure share financial companies holder group april andr hoffmann took role pool spokesman detailed httpwwwrochecomhomecompany information group presented comgovcomgovbylawshtm annual report corporate governance millions chf additional information relating corporate auditing services governance auditrelated services tax consultancy services group structure shareholders total roches operating businesses organised two divisionspharmaceuticals diagnostics group auditors statutory auditors pharmaceuticals division comprises three elected year annual general meeting business segments roche prescriptiongenentech prescription chugai prescription sale ernst young ltd received following remuner consumer health otc business resulted ation services auditors ofgenentech inthe transfer ofroches otc business bayer ag chugai december chugais otc business lion corporation december millions chf diagnostics division consists offive business genentech chugai audits areas diabetes care near patient testing cen consulting services provided tralized diagnostics molecular diagnostics genentech chugai applied science business activities carried total group subsidiaries associated companiessignificant subsidiaries associated companies listed note roche group consolidated financial statements sub sidiaries associated companiespages major shareholders listed notes roche group consolidated financial state ments equityand related partiespages notes financial statements ofroche holding ltd andr hoffmann andreas oeri serve board ofdirectors representatives ofthe share holders pooled voting rights receive remuneration set table remuneration members board directorsaboveno relationships exist shareholders pooled voting rights crossshareholdings capital structure information roches capital structure pro vided notes financial statements roche holding ltd additional details contained articles incorporation roche holding ltd changes equity detailed notes financial statements roche holding ltd httpwwwrochecomhomecompany comgovcomgovartihtm annual report corporate governance company share capital board directors established system swiss francs divided fully paid controls overseen audit bearer shares nominal value swiss franc corporate governance committee consists limitations transfer following elements shares shares maximum voting reports financial operating risks rightsupon depositshares voted without internal audits restrictions compliance officer authorised conditional capital safety environment department addition nes issued corporate sustainability committee bearer formthey form part share scientific ethics advisory group seag capital confer voting rightseach nes con issues relating genetics genetic engi fers rights one share participate neering established available earnings liquidation proceeds year several blackout periods imposed following repayment share capitalroches senior employees prohibited nes provisions securing claims trading company stock following rights pertaining thereto described ofthe blackout periods effect articles ofincorporation ofroche holding ltd january february information debt instruments april april issued outstanding bonds july july found note roche group consoli october october dated financial statements debt blackout periods changed chairman additional information employee stock ofthe board ofdirectors ifcircumstances warrant options found note board ofdirectors held total offive meetings roche group consolidated financial statements board committees met follows employee stock options equity com pensation benefits presidium ofthe board ofdirectorsnomi roche issued options apart nation committeefive meetings awarded employees issued audit corporate governance commit connection debt instruments teefour meetings neither options awarded employees finance investment committee three debt instruments issued meetings effect roches share capital remuneration committeefour meetings management contracts fall board directors executive committee within meaning ofsubsection ofthe swx information member board corporate governance directive directors including years elected years terms end participatory rights shareholders executive committee listed pages participatory rights shareholders fully curricula vitae information defined roches articles incorporation board executive committee members roche shares issued bearer including information board memberships restrictions admission annual general available internet meetingswith exception shares must none ofthe nonexecutive members ofthe board directors member executive committee roche group sub httpwwwrochecomhomecompany sidiaries three financial years preceding comgovhtm current reporting period httpwwwrochecomhomecompany internal organisation board direc comgovcomgovbylawshtm tors division ofauthority responsibil httpwwwrochecomhomecompany ities board management comgovcomgovartihtm governed bylaws annual report corporate governance deposited within specified period date information policy meeting admittance card must provided articles incorpo issued shareholders name provided ration corporate notices published articles incorporation share swiss official gazette commerce schwei holder elect represented another zerisches handelsamtsblatt daily shareholder annual general meeting newspapers designated board directors articles incorporation contain restrictions basler zeitungfinanz und wirtschaftlagefile exercise ofvoting rightsand quo tempsneue zrcher zeitung rum requirements stipulated roche reports halfyear fullyear results ofthe articles ofincorporationshare inbusiness reports published print online holders representing shares nominal value formats media events addition first least swiss francs request place thirdquarter sales figures published ment items business agenda year april octobercurrent dates ofpubli annual general meeting must done cations available english german later days date ofthe meeting internet relevant information documentsinclud change control defensive measures ing media releases presentations articles incorporation contain provi analyst investor conferences avail sions mandatory bid ruleswiss law applies able english german internet changeofcontrol clauses publications ordered email components remuneration based roche fax telephone baselwebmasterrochecom nes would terminated event ofan acqui tel fax sition vesting period restrictions pre contact address investor relations existing awards would removedso f hoffmannla roche ltd investor relations options could immediately exercised corporate finance basel switzerland tel fax additional informationincluding details spe cific contact personsis available internet nonapplicabilitynegative disclosure expressly noted information con tained mentioned herein nonapplicable omission construed negative declara tion according requirements swx corporate governance directive including commentary httpwwwrochecomhomecompany comgovcomgovartihtm httpwwwrochecomhomemediamedeventshtm httpwwwrochecomhomeinvestorsinvcontacthtm annual report corporate governance compliance officer compliance officer committed ensuring roche corporate principles consistently complied throughout roche group also serves contact person shareholders employees customers suppliers general public issues relating implementation compliance principles employees parties become aware violations roche corporate principles bring attention managers supervisors report compliance officer andreas greuter direct phone number disclosures treated confidentialemployees make disclosures penalised company sobut immune prosecution legal violations compliance officer sub mits regular reports audit corporate governance committee annual report making diabetes easier live number people diabetes risen sharply recent years according estimate reach million situation already described global epidemic diabetes associated serious complications including blindness heart attack stroke kidney damage limb amputations many problems prevented improved regular blood glucose monitoring right insulin regimen means health systems well patients stand benefit thirty years ago idea people diabetes mon itoring glucose went daily lives seemed unthinkable norm roche diagnostics major hand bringing change today small easytouse glucose meters like accuchek compact match pre cision accuracy laboratory latest software personal digital assistants makes possible manage glucose insulin data together story doesnt end want make life even simpler safer people diabetes example finding ways measure blood glucose without take blood sample devel oping insulin pumps allow continuous insulin delivery longterm goal create artificial pancreas would huge step forward fight diabetes monitoring monitoring devices people dia betes benefits using compact hightech self monitoring device real patients taking anticoagulants need quick reliable information coagulation status specific diagnostic tests systems play vitalrole monitoring types therapy well example help doctors track patients responses antihiv therapy necessary make right treatment changes right time annual report selfmonitoring gives independence security short better quality life gudrun schindler lives schwbische alb region germanyadvises people diabetes knows shes talking last years checking blood glucose several times day roche accuchek systems predisposition early detecion prevention diagnosis therapy monitoring annual report finance brief net income millions chf net income continuing businesses exceptional items millions chf ebitda continuing businesses millions chf net liquidity yearend millions chf debt yearend millions chf stock price nonvoting equity security genussschein yearend chf excluding gain labcorp transactions annual report finance roche finance contributed significantly excellent group results supporting divestment otc business creating conditions balanced financial income billion swiss francs proceeds otc divestment covered billion swiss francs cost acquisition igen debt reduced billion swiss francs resulting significantly lower interest expenses also continued reduce risk exposures financial investments foreign exchange transactions finance activities coupled strong cash generation pharmaceuticals diagnostics evidenced ebitda billion swiss francs led increase groups net liquidity billion swiss francs billion swiss francs ratio equity minority interests total assets improved erich hunzikerchieffinancial officer annual report key figures key figures millions chf roche group continuing businessesa change change chf lc chf lc sales research development ebitdab operating profit exceptional items operating profit financial income net income exceptional itemsc net income epsdbefore exceptional items chf epsdin chf research development sales ebitda sales operating profit exceptional items sales effective tax rate net income sales roche group roche group december december net liquidity total assets equity minority interests debt equity ratioe debtequity ratiof continuing businesses includes pharmaceuticals diagnostics businesses treasury corporate activities consumer health otc vitamins fine chemicals reported discontinuing businesses b ebitda earnings exceptional items interest financial income tax depreciation amortisation including impairment corresponds operating profit exceptional items depreciation amortisation including impairment c net income exceptional items eps exceptional items calculated shown eps earnings per share nonvoting equity security diluted e equity ratio equity minority interests percentage total assets f debtequity ratio debt percentage equity including minority interests lc local currencies annual report finance brief market sales growth sales two core businesses local currencies strongest growth highmargin products business areas improved profitability pharmaceuticals diagnostics operating profit continuing businesses exceptional items increased local currencies pharmaceuticals operating profit margin exceptional items increased percentage points diagnostics operating profit margin exceptional items increased percentage points continued high investment rd billion swiss francs funding inlicensing deals selective disposals noncore products divestment otc business sale roche consumer health bayer sale chugais otc business lion corporation bayer deal includes five pharmaceuticals production facilities reducing asset levels transactions realised total pretax gains billion swiss francs deals cash transactions completion igen acquisition acquisition completed february billion swiss francs strengthens access diagnostics immunochemistry sector continued debt restructuring restructuring highinterest debt instruments retired debt decreased billion swiss francs interest expenses reduced million swiss francs exceptional pretax income million swiss francs bond conversion redemption reduced financial risks risk exposures financial assets foreign exchange transactions reduced increased net liquidity increased billion swiss francs billion swiss francs increased net income increase net income billion swiss francs increase net income continuing businesses exceptional items billion swiss francs annual report table contents finance roche group financial review roche group consolidated financial statements notes roche group consolidated financial statements report group auditors multiyear overview supplementary net income eps information roche securities roche holding ltd basel financial statements notes financial statements appropriation available earnings report statutory auditors annual report financial review operating results continuing businesses exceptional items sales increase sales core businesses gaining market share roche group recorded sales billion swiss francs continuing businesses represents increase local currencies swiss francs growth divisions well ahead respective market growth pharmaceuticals driven roches successful oncology franchise including firsttime sales avastin tarceva million swiss francs respectively also strong growth virology franchise including pegasyscopegus transplantation franchise products cellcept valcytecymevene diagnostics major drivers diabetes care molecular diagnostics immunodiagnostics sales grew well ahead market rate sales continuing businessesin millions chf change change chf local currencies pharmaceuticals roche prescription genentech prescription chugai prescription diagnostics sales continuing businesses divisional results operating profit exceptional items increased local currencies swiss francs billion swiss francs pharmaceuticals increased operating profit margin increase percentage points diagnostics improved percentage points achieved strong sales growth increased income product divestments covering additional spending newly launched products upcoming launches investment development pipeline divisional results continuing businesses exceptional items millions chf operating operating profit divisional ebitda profit exceptional sales third exceptional items parties ebitda sales items sales pharmaceuticals roche prescription genentech prescription chugai prescription diagnostics group total continuing businesses pharmaceuticals roche prescription genentech prescription chugai prescription diagnostics group total continuing businesses annual report financial review pharmaceuticals operating profit increased local currencies swiss francs billion swiss francs representing sales compared ebitda showed similarly strong result increasing billion swiss francs rise local currencies ebitda margin increased higher profitability driven largely local currency sales growth underproportional growth marketing distribution administration amortisation intangible assets investments research development grew local currencies reach billion swiss francs sales includes inlicensing investments million swiss francs funded gains product disposals million swiss francs roche prescription operating profit margin roche prescription business increased percentage points marketing distribution amortisation intangible assets grew underproportionately investment research development grew significantly faster sales driven strong development pipeline inlicensing investments royalty expenses licensed products also increased increases largely funded selective disposals noncore products genentech prescription business achieved strong sales profit growth operating profit upby local currencies swiss francs operating profit margin increased despite additional spending marketing promotional programs support commercial pipeline products primarily avastin tarceva raptiva xolair mabtherarituxan herceptin additional expenses also incurred expansion infrastructure necessary support sales growth charges million swiss francs related discontinuation commercialisation nutropin depot chugai prescriptionthis business posted operating profit million swiss francs operating profit margin reached compared strong performance result sales growth second halfyear operating profitability significantly lower comparative period driven restructuring expenses early retirement programme without impact showed significantly higher operating profitability second half year basically due japanese pattern relatively low sales first quarter following high fourthquarter sales previous year diagnostics operating profit increased billion increase operating margin percentage points ebitda increased billion swiss francs resulting ebitda margin main driver results sales growth addition higher royalty income broadly equivalent net effect results income legal settlements product disposals costs disetronic restructuring charges additional amortisation expenses intangible assets arising igen acquisition basically equivalent royalty expenses previously paid igen includes costs corporate headquarters annual report financial review group operating results operating profit continuing businesses exceptional items millions chf change change chf local currencies sales cost sales gross profit marketing distribution research development administration amortisation intangible assets operating income operating expense operating profit exceptional items continuing businesses gross profit gross profit margin improved percentage points reflecting growth high margin products well effects continuing productivity improvements marketing distribution increase due support newly launched products pegasyscopegus fuzeon xolair raptiva avastin tarceva well marketing activities growing diagnostics business however marketing distribution percentage sales decreased percentage points increase expenditure less sales growth research development increase mainly due significantly increased activities support strong development pipeline includes inlicensed optin compounds research development costs percentage sales increase percentage point compared forpharmaceuticals accounts groups research development expenses increased percentage points sales administrationthe increase part due alignment infrastructure genentech reflecting continuing growth business increased legal expenses amortisation intangible assets increase due intangible assets acquired disetronic igen acquisitions results include million swiss francs igen representing months since acquisition full years charge million swiss francs disetronic results included months amortisation operating income increase due product divestments soriatane gains product divestments totalling million swiss francs compared million swiss francs gains used fund increased level inlicensing activity royalty income also increased operating expensethis increase basically due higher royalty expenses inlicensed products mabtherarituxan xolair addition million swiss francs charges intangible asset impairment particular resulting genentechs decision discontinue commercialisation nutropin depot annual report financial review discontinuing operations discontinuing operationsin millions chf sales operating profit exceptional items otc businesssales nonprescription medicines increased swiss francs million swiss francs operating profit exceptional items million swiss francs includes restructuring costs million swiss francs vitamins fine chemicals business effective september receiving final regulatory approvals group completed sale global vitamins fine chemicals business dutch company dsm results roche group include results vitamins fine chemicals business september exceptional items nonoperating results exceptional items nonoperating resultsin millions chf continuing discontinuing businesses businesses group operating profit exceptional items amortisation goodwill major legal cases changes group organisation operating profit income associated companies financial income exceptional income bond conversion redemption profit taxes income taxes profit taxes minority interests net income earnings per share nonvoting equity security basic chf diluted chf amortisation goodwill goodwill amortisation disetronic igen acquisitions million swiss francs versus million swiss francs million swiss francs respectively roche continued amortise goodwill including held genentech presents exceptional item view international financial reporting standards changes implemented annual report financial review major legal casesthere significant developments additional income expenses recorded changes group organisationin group announced sale roche consumer health including five roche prescription manufacturing sites bayer sale substantially completed yearend covering majority sites businesses involved addition chugai completed sale otc business japan lion corporation total pretax gain sales billion swiss francs includes impairments restructuring charges roches prescription business totalling million swiss francs results include losses sale vitamins fine chemicals business totalling million swiss francs operating profit overall operating profit increased billion swiss francs local currencies follows billion swiss franc realised gain sale consumer health otc business compared billion swiss franc loss disposal vitamins fine chemicals business exceptional items operating profit increased local currencies billion swiss francs income associated companies result associates significant financial income financial income showed improvement compared net income equity securities million swiss francs compared net expense million swiss francs comparative result includes impairment losses million swiss francs compared million swiss francs ongoing income equity debt securities decreased due lower holdings total interest expenses million swiss francs reduction due retirement various debt instruments refinancing obligations covering convertible debt instruments carried netforeign exchange gains million swiss francs compared million swiss francs following reduction foreign exchange exposures full analysis financial income given note consolidated financial statements exceptional income bond conversion redemption part continuing refinancing restructuring groups debt lyons iv lyons iii notes called redemption group also redeemed part chameleon bond public tender lyons iv redemption call almost outstanding notes called conversion genentech shares holders addition group reassessed likely future cash outflows lyons v notes concluded appropriate consider first call date july probable date cash flows accordingly using effective interest rate method group recorded pretax expense million swiss francs allow accreted debt value meet issue price plus accrued original issue discount oid july net pretax gain million swiss francs arose transactions primarily groups partial disposal interest genentech conversion lyons iv notes due material impact presented exceptional item income statement income taxes groups continuing businesses effective tax rate compared rate included recognition certain previously unrecognised tax losses local effects offset negative effects tax rate conversion redemption bonds relatively high total group effective tax rate results caused impairment charges vitamins fine chemicals business reconciliation effective tax rate given note consolidated financial statements minority interests income applicable minorities increased due continually improving profit contribution genentech chugai million swiss francs relate genentech million swiss francs chugai annual report financial review net incomethe group increased net income following improved operating results exceptional gains tax minority interests billion swiss francs otc divestment billion swiss francs bond conversions redemptions excluding exceptional items net income continuing businesses basis increased million swiss francs cash flows net liquidity cash flow statementin millions chf cash generated business operations increase decrease working capital income costs major legal cases received paid operating cash flows operating activities income taxes income taxes paid activities operating activities investing activities financing activities net effect currency translation cash increase decrease cash terms agreement bayer majority proceeds divestment consumer health otc business amounting million swiss francs transferred group january amounts included table see also note consolidated financial statements operating cash flows groups business operations continued show strong cash generation billion swiss francs driven continued growth ebitda income taxes paid normal level compared included large income tax receivables recovered tax authorities cash flows otc business included figures ebitda business million swiss francs million swiss francs cash flows vitamins fine chemicals business included figures ebitda business million swiss francs investing cash flowsthe largest investing cash flow billion swiss francs paid respect igen acquisition investing cash flows also include expenditure property plant equipment large net cash inflow sales part groups portfolio marketable securities order fund repayment debt instruments also vitamin case payments disposal otc business increased cash billion swiss francs main proceeds billion swiss francs received bayer january financing cash flows significant financing cash flows relate dividend payments redemption debt instruments dividends paid billion swiss francs billion swiss francs cash used redemption debt instruments billion swiss francs used lyons iii notes chameleon bonds compared billion swiss francs used bullet bonds lyons ii notes redemption conversion lyons iv notes cash impact million swiss francs debt obligation almost entirely settled delivery genentech shares cash flows also included billion swiss francs proceeds three issues groups european medium term note programme outflow billion swiss francs refinancing instruments covering convertible debt obligations annual report financial review net liquidityin millions chf december december change cash marketable securities receivable bayer group collected january financial longterm assets restricted cash derivative financial instruments net equity instruments financial assets longterm debt shortterm debt total debt net liquidity net liquidity increased main driver strong cash inflow operating activities billion swiss francs inflow billion swiss francs divestment consumer health otc business covered outflow billion swiss francs acquisition igen lyons iv notes conversion reduced debt increased net liquidity billion swiss francs lyons iii chameleon transactions affect debt cash therefore little effect net liquidity balance sheet balance sheetin millions chf december december change longterm assets current assets total assets equity minority interests noncurrent liabilities current liabilities total equity minority interests liabilities longterm assets igen acquisition increased goodwill intangible assets billion swiss francs thesale otc business reduced longterm assets billion swiss francs fall usdollar swiss franc end reduced longterm assets swiss franc terms since many groups production facilities intangible assets us dollar denominated current assets current assets increased billion swiss francs proceeds sale otc business cash generated operations current assets decreased billion swiss francs cash paid igen billion swiss francs cash used payment dividends billion swiss francs cash used redemption lyons iii notes partial redemption chameleon bonds sale otc business reduced current assets mainly inventories trade receivables billion swiss francs equity significant movements net income billion swiss francs dividend payment billion swiss francs annual report financial review minority interests conversion lyons iv notes led increase minority ownership genentech swiss franc terms offset fall us dollar swiss franc noncurrent liabilities major movement sumo bonds book value billion swiss francs due march classified shortterm debt partial redemption chameleon bonds reduced longterm debt billion swiss francs movement us dollar rates reduced swiss francs carrying value groups us dollar denominated debt instruments current liabilitiesthe conversion redemption lyons iv lyons iii notes reduced shortterm debt billion swiss francs partly compensated reclassification sumo bonds longterm debt strong financial condition group remains solidly financed equity including minority interests representing total assets total assets financed longterm international financial reporting standards roche group using international financial reporting standards ifrs report consolidated results since since late international accounting standards board iasb published number new revised standards group implement effective january fully discussed note consolidated financial statements changes group expects significant impact described equity compensation plans fair value equity compensation plans awarded employees estimated grant date recorded expense vesting period change applied retrospectively using certain transitional restrictions based initial work carried applying transitional restrictions group estimates impact operating income net income would approximately million swiss francs million swiss francs respectively due transitional rules indicative future impacts goodwill amortisation effective january amortisation goodwill cease goodwill continue tested impairment standard requires prospective application standard applied goodwill amortisation expenses million swiss francs would recorded net income would million swiss francs higher recognition intangible assets revised standards intangible assets business combinations typically result intangible assets recognised acquisitions inlicensing collaborations alliances previously financial instruments group already fully applies existing ias financial instruments done since changes standards financial instruments expected major effect equity minority interests minority interests included part groups equity separate category balance sheet increase groups equity million swiss francs effective january group expect new revised standards significant effect groups results financial position annual report financial review financial risks valueatrisk earningsatrisk analysis tools valueatrisk var calculations used indicate within ranges value respective assets liabilities may fluctuate certain probability certain time period holding period var measure statistical measure implicitly assuming value changes recent past indicative value changes future market shocks included calculation unless recently observed group conducts additional stress testing take possibilities consideration group uses statistically relevant observation periods applies holding periods reflect time period required change respective risk exposure deemed appropriate longer holding periods probability higher value changes increases var measure earningsatrisk ear equivalent var methodology rather potential value changes indicates potential changes profits losses certain probability certain time period constraints limitations apply methodology var ear figures interest rate risks measured using historical simulation approach historical scenario representing price rate changes individual instruments specific day period past financial instruments fully revalued using valuation models total change value earnings determined var figures based delta normal approach assuming normal market conditions var ear calculations based confidence level holding period days group predict future market movements var ear figures given represent actual losses expected might incurred financial assets liabilities possible worst loss period stated consider effect favourable changes market rates foreign exchange risk group operates across world exposed movements foreign currencies affecting net income financial position expressed swiss francs growth continuing businesses local local currencies currencies chf chf sales operating profit exceptional items exchange rates swiss franc december average december average usd eur gbp jpy annual report financial review average us dollar considerably weaker swiss franc euro slightly stronger swiss franc total negative currency effect sales growth continuing businesses operating profit growth percentage points absolute terms sensitivity group sales continuing businesses change us dollar swiss franc swiss francs average approximately million swiss francs corresponding sensitivities euro yen approximately million swiss francs million swiss francs respectively group monitors net currency exposures appropriate enters transactions aim preserving value assets commitments anticipated transactions group uses forward contracts swaps foreign currency options optimise certain anticipated foreign exchange revenues cash flows financing transactions group pursued strategy continuously lockin favourable developments foreign exchange rates entering derivative contracts thereby reducing exposure potential future moves foreign exchange rates foreign exchange transaction var remained low level foreign exchange risks millions chf december december change var monetary positions interest rate risk interest rate risk arises movements interest rates could adverse effects groups net income financial position changes interest rates cause variations interest income expenses interestbearing assets liabilities addition affect market value certain financial assets liabilities instruments appropriate group uses financial derivatives swaps options manage interest rate risk group reduced outstanding debt order achieve better match term structure assets liabilities group also swapped sizeable part remaining debt floating interest rates consequence exposure potential changes interest rates decreased interest rate var measuring potential change net market value interest rate sensitive assets liabilities declined comparatively small risks repricing refinancing contained reasonable levels however earningsatrisk ear slightly increased mainly result generally higher interest rate level allows room downward changes interest rates interest rate risksin millions chf december december change var instruments sensitive interest rates ear instruments sensitive interest rates market risk financial assets changes market value cash marketable securities affect net income financial position group market risk arises movements stock prices interest rates foreign exchange rates annual report financial review equity allocation groups portfolio cash marketable securities reduced around billion swiss francs billion swiss francs december currency allocation funds changed extent well small shift groups asset allocation resulted slightly increased var position compared last year calculated var figures exclude positions genentech chugai run treasury operations independently market risk financial assets millions chf december december change var cash marketable securities annual report roche group consolidated financial statements reference numbers indicate corresponding notes consolidated financial statements consolidated income statement year ended december millions chf continuing discontinuing businesses businesses group sales cost sales gross profit marketing distribution research development administration amortisation intangible assets operating income operating expenses operating profit exceptional items amortisation goodwill major legal cases changes group organisation operating profit income associated companies financial income exceptional income bond conversion redemption profit taxes income taxes profit taxes minority interests net income earnings per share nonvoting equity security basic chf diluted chf annual report roche group consolidated financial statements consolidated income statement year ended december millions chf continuing discontinuing businesses businesses group sales cost sales gross profit marketing distribution research development administration amortisation intangible assets operating income operating expenses operating profit exceptional items amortisation goodwill major legal cases changes group organisation operating profit income associated companies financial income profit taxes income taxes profit taxes minority interests net income earnings per share nonvoting equity security basic chf diluted chf annual report roche group consolidated financial statements consolidated balance sheetin millions chf december december longterm assets property plant equipment goodwill intangible assets investments associated companies financial longterm assets longterm assets deferred income tax assets postemployment benefits total longterm assets current assets inventories accounts receivable current income tax assets current assets marketable securities receivable bayer group collected january cash cash equivalents total current assets total assets equity share capital nonvoting equity securities genussscheine pm pm equity instruments retained earnings fair value reserves total equity minority interests noncurrent liabilities longterm debt deferred income tax liabilities postemployment benefits provisions noncurrent liabilities total noncurrent liabilities current liabilities shortterm debt current income tax liabilities provisions accounts payable accrued current liabilities total current liabilities total equity minority interests liabilities pm pro memoria nonvoting equity securities nominal value see note annual report roche group consolidated financial statements consolidated statement changes equityin millions chf year ended december share capital balance january december nonvoting equity securities genussscheine balance january december pm pm equity instruments balance january acquisition disetronic conversion helveticus bonds refinancing instruments covering convertible debt obligations movements year balance december retained earnings balance january net income dividends paid balance december fair value reserves balance january changes fair value attributable availableforsale investments qualifying cash flow hedges fair value gains losses attributable availableforsale investments qualifying cash flow hedges recognised income statement fair value gains losses attributable qualifying cash flow hedges transferred adjust initial measurement acquisition cost assets carrying amount hedged assets liabilities deferred income taxes minority interests currency translation gains losses balance december total equity december pm pro memoria nonvoting equity securities nominal value see note annual report roche group consolidated financial statements consolidated cash flow statementin millions chf year ended december cash flows operating activities cash generated operations increase decrease working capital vitamin case payments igen litigation genentech legal cases payments made defined benefit postemployment plans utilisation restructuring provisions utilisation provisions operating cash flows cash flows operating activities income taxes paid income taxes paid total cash flows operating activities cash flows investing activities purchase property plant equipment purchase intangible assets disposal property plant equipment disposal intangible assets disposal products acquisitions subsidiaries associated companies divestments subsidiaries associated companies interest dividends received sales marketable securities purchases marketable securities investing cash flows total cash flows investing activities cash flows financing activities proceeds issue longterm debt instruments repayment longterm debt instruments increase decrease longterm debt refinancing instruments covering convertible debt obligations transactions equity instruments increase decrease shortterm borrowings interest dividends paid genentech chugai stock repurchases exercised employee stock options genentech financing cash flows total cash flows financing activities net effect currency translation cash cash equivalents increase decrease cash cash equivalents cash cash equivalents beginning year cash cash equivalents end year terms agreement bayer majority proceeds divestment consumer health otc business amounting million swiss francs transferred group january amounts included table see also note annual report notes roche group consolidated financial statements reference numbers indicate corresponding notes consolidated financial statements summary significant accounting policies basis preparation consolidated financial statements consolidated financial statements roche group prepared accordance international financial reporting standards ifrs prepared using historical cost convention except disclosed accounting policies certain items including derivatives availableforsale investments shown fair value approved issue board directors january subject approval shareholders february preparation consolidated financial statements requires management make estimates assumptions affect reported amounts revenues expenses assets liabilities disclosure contingent liabilities date financial statements future estimates assumptions based managements best judgement date financial statements deviate actual circumstances original estimates assumptions modified appropriate year circumstances change necessary comparatives reclassified extended previously reported results take account presentational changes consolidation policy financial statements consolidated financial statements roche holding ltd company registered switzerland subsidiaries group subsidiaries companies controlled directly indirectly roche holding ltd control defined power govern financial operating policies enterprise obtain benefits activities control normally evidenced roche holding ltd owns either directly indirectly voting rights potential voting rights companys share capital special purpose entities consolidated substance relationship special purpose entity controlled group companies acquired year consolidated date control transferred group subsidiaries divested included date control passes group companies acquired exclusively resold next twelve months consolidated classified financial assets heldfortrading carried fair value intercompany balances transactions resulting unrealised income eliminated full investments associated companies accounted equity method companies group exercises power exercise significant influence control normally evidenced group owns voting rights potential voting rights company balances transactions associated companies result unrealised income eliminated extent groups interest associated company interests joint ventures reported using linebyline proportionate consolidation method segment reporting groups primary format segment reporting business segments secondary format geographical segments risks returns groups operations primarily determined different products group produces rather geographical location groups operations reflected groups divisional management organisational structure groups internal financial reporting systems group two divisions pharmaceuticals diagnostics disposal september group third division vitamins fine chemicals within pharmaceuticals division three subdivisions roche prescription genentech prescription chugai prescription three subdivisions separate management reporting structures within pharmaceuticals division considered separately reportable segments consumer health otc business also separately reportable business segment presented discontinuing business certain corporate activities reasonably allocated reportable segments costs corporate headquarters reported annual report notes roche group consolidated financial statements others groups geographical segments determined geographical location similarity economic environments transfer prices business segments set arms length basis divisional assets liabilities consist property plant equipment goodwill intangible assets trade receivablespayables inventories segment assets liabilities consist assets liabilities reasonably attributed reported business segments include pension assetsliabilities provisions non segment assets liabilities mainly include current deferred income tax balances financial assets liabilities principally cash marketable securities investments debt capital expenditure comprises additions goodwill intangible assets additions property plant equipment including arising acquisitions foreign currency translation group companies use local currency measurement currency certain group companies use currencies namely us dollars swiss francs euros measurement currencies usefully represents results financial positions companies given local economic conditions circumstances local transactions currencies initially reported using exchange rate date transaction gains losses settlement transactions gains losses translation monetary assets liabilities denominated currencies included income except qualifying cash flow hedges arise monetary items substance form part groups net investment foreign entity deferred equity upon consolidation assets liabilities group companies using measurement currencies swiss francs foreign entities translated swiss francs using yearend rates exchange sales costs expenses net income cash flows translated average rates exchange year translation differences due changes exchange rates beginning end year difference net income translated average yearend exchange rates taken directly equity divestment foreign entity identified cumulative currency translation differences relating foreign entity recognised income part gain loss divestment revenues cost sales sales represent amounts received receivable goods supplied customers deducting trade discounts cash discounts volume rebates excluding sales value added taxes revenues sale products recognised upon transfer customer significant risks rewards usually upon shipment trade discounts cash discounts volume rebates recorded accrual basis consistent recognition related sales revenues recorded earned services performed cost sales includes corresponding direct production costs related production overhead goods sold services rendered startup costs validation achievement normal production capacity expensed incurred royalty income recognised accrual basis accordance economic substance agreement reported part operating income research development research costs charged income incurred development costs capitalised intangible assets particular probable future economic benefits flow group intangible assets amortised straightline basis period expected benefit reviewed impairment balance sheet date development costs charged income incurred since criteria recognition asset met inlicensing milestone upfront receipts payments certain group companies notably genentech receive thirdparties upfront milestone similar nonrefundable payments relating sale licensing products technology revenue associated performance milestones recognised based achievement milestones defined respective agreements revenue nonrefundable upfront payments licence fees initially reported deferred income recognised income earned period development collaboration manufacturing obligation payments made group companies third parties associated companies annual report notes roche group consolidated financial statements items charged income research development costs unless probable future economic benefits flow group normally evidenced regulatory approval case capitalised development costs amortised described practice means licensing milestone payments pharmaceutical products expensed incurred cases yet gained regulatory approval receipts payments consolidated subsidiaries genentech chugai roche group subsidiaries eliminated consolidation except extent impacts minority interests employee benefits wages salaries social security contributions paid annual leave sick leave bonuses nonmonetary benefits accrued year associated services rendered employees group group provides longterm employee benefits cost accrued match rendering services employees concerned group operates number defined benefit defined contribution plans throughout world cost year defined benefit plans determined using projected unit credit method reflects service rendered employees dates valuation incorporates actuarial assumptions primarily regarding discount rates used determining present value benefits projected rates remuneration growth longterm expected rates return plan assets discount rates based market yields highquality corporate bonds country concerned differences assumptions actual experiences effects changes actuarial assumptions allocated estimated average remaining working lives employees differences exceed defined corridor past service costs allocated average period benefits become vested pension assets liabilities different defined benefit plans offset unless group legally enforceable right use surplus one plan settle obligations plan recognition pension assets limited net total unrecognised actuarial losses past service costs present value future refunds plans reductions future contributions plans groups contributions defined contribution plans charged income statement year relate group operates several equity compensation plans including separate plans genentech chugai fixed plans roche option plan equivalent plans genentech chugai expense recognised date issue exercise price greater equal fair value underlying equity instrument date issue subsequent cash flows exercises vested grants recorded equity case genentech chugai plans balance sheet minority interests performance related variable plans roche performance share plan stock appreciation rights expense accrued vesting period difference exercise price fair value underlying equity instrument taxation income taxes include taxes based upon taxable profits group including withholding taxes payable distribution retained earnings within group taxes based income property capital taxes included within operating expenses financial income according nature liabilities income taxes mainly withholding taxes could arise remittance retained earnings principally relating subsidiaries recognised probable intention remit earnings deferred income tax assets liabilities recognised temporary differences tax bases assets liabilities carrying amounts financial statements deferred income tax assets relating carryforward unused tax losses recognised extent probable future taxable profit available unused tax losses utilised current deferred income tax assets liabilities offset income taxes levied taxation authority legally enforceable right offset deferred income taxes determined based currently enacted tax rates applicable tax jurisdiction group operates annual report notes roche group consolidated financial statements property plant equipment property plant equipment initially recorded cost purchase construction depreciated straightline basis except land depreciated estimated useful lives major classes depreciable assets follows buildings land improvements years machinery equipment years office equipment years motor vehicles years estimated useful life assets regularly reviewed necessary future depreciation charge accelerated investment grants similar assistance projects initially recorded deferred income noncurrent liabilities subsequently recognised income useful lives related assets repairs maintenance costs recognised expenses incurred borrowing costs capitalised leases leases property plant equipment group substantially risks rewards ownership classified finance leases finance leases capitalised start lease fair value present value minimum lease payments lower rental obligation net finance charges included debt assets acquired finance leases depreciated accordance groups policy property plant equipment interest element lease payment charged income lease term based effective interest rate method leases substantially risks rewards ownership transferred group classified operating leases payments made operating leases charged income straightline basis period lease business combinations goodwill business combinations accounted using purchase method accounting cost acquisition cash paid plus fair value date exchange purchase consideration given exchange control net assets acquired company cost acquisition also includes directly attributable incidental costs acquired identifiable assets liabilities initially recognised fair value group acquire ownership acquired company assets liabilities recognised fair value extent groups interest minority interest recorded minoritys proportion preacquisition carrying amounts acquired assets liabilities goodwill recorded surplus cost acquisition groups interest fair value identifiable net assets acquired goodwill fair value adjustments recorded assets liabilities acquired company recorded local currency company goodwill amortised useful life straightline basis estimated useful life goodwill years goodwill may also arise upon investments associated companies surplus cost investment groups share fair value net identifiable assets goodwill recorded within investments associated companies amortisation included within income associated companies intangible assets patents licences trademarks intangible assets initially recorded cost assets acquired business combination fair value allocated acquisition accounting acquired business combination initial fair value cost intangible assets amortised useful lives straightline basis estimated useful life lower legal duration economic useful life exceed years estimated useful life assets regularly reviewed necessary future amortisation charge accelerated impairment property plant equipment intangible assets evidence asset may impaired recoverable amount asset calculated impairment assessment carried recoverable amount asset higher net selling price value use less carrying amount carrying amount reduced recoverable annual report notes roche group consolidated financial statements value reduction reported income statement impairment loss value use calculated using estimated cash flows generally fiveyear period extrapolating projections subsequent years discounted using appropriate longterm pretax interest rate impairment loss arises useful life asset question reviewed necessary future depreciationamortisation charge accelerated impairment financial assets discussed financial assets policy inventories inventories stated lower cost net realisable value cost finished goods work process comprises raw materials direct labour directly attributable costs overheads based upon normal capacity production facilities borrowing costs included cost determined using weighted average method net realisable value estimated selling price less cost completion selling expenses accounts receivable accounts receivable carried original invoice amount less allowances made doubtful accounts allowance recorded difference carrying amount recoverable amount objective evidence group able collect amounts due cash cash equivalents cash cash equivalents comprise cash hand time call current balances banks similar institutions readily convertible known amounts cash subject insignificant risk changes value maturity three months less date acquisition definition also used cash flow statement equity instruments groups holdings equity instruments recorded deduction equity original cost acquisition consideration received subsequent resale equity instruments movements reported changes equity instruments acquired primarily meet obligations may arise respect certain groups debt instruments debt instruments debt instruments initially reported cost proceeds received net transaction costs subsequently reported amortised cost using effective interest method extent debt instruments hedged qualifying fair value hedges carrying value hedged item adjusted fair value movement attributable risk hedged discount net proceeds received principal value due redemption amortised duration debt instrument recognised part interest expense income statement issue convertible debt instruments cost liability portion initially calculated using market interest rate equivalent nonconvertible instrument remainder net proceeds allocated equity conversion option reported equity deferred income tax liabilities equity conversion option shares consolidated subsidiary portion net proceeds attributable option recorded within minority interest liability element subsequently reported amortised cost amortisation debt discount release deferred tax liabilities recognised income statement duration debt instrument value equity conversion option recorded equity changed future periods limited conversion preferred stock substance financial liability rather equity instrument therefore classified longterm debt balance sheet related dividend payments treated interest expense provisions provisions recognised legal constructive obligation incurred probably lead outflow resources reasonably estimated particular restructuring provisions recognised group detailed formal plan either commenced implementation announced provisions recorded estimated ultimate liability expected arise taking account foreign annual report notes roche group consolidated financial statements currency effects arising translation measurement currency swiss francs time value money material contingent liability disclosed existence obligation confirmed future events amount obligation measured reasonable reliability contingent assets recognised disclosed inflow economic benefits probable fair values fair value amount financial asset liability instrument could exchanged knowledgeable willing parties arms length transaction determined reference quoted market prices use established estimation techniques option pricing models estimated discounted values cash flows fair values balance sheet date approximately line reported carrying values unless specifically mentioned notes consolidated financial statements financial assets financial assets principally investments including marketable securities classified either heldfor trading availableforsale heldtomaturity originated group heldfortrading financial assets acquired principally generate profit shortterm fluctuations price heldtomaturity financial assets securities fixed maturity group intent ability hold maturity financial assets originated group loans longterm financial assets created group acquired issuer primary market financial assets considered availableforsale financial assets initially recorded cost including transaction costs purchases sales recognised settlement date heldfortrading financial assets subsequently carried fair value changes fair value recorded financial income period arise heldtomaturity financial assets subsequently carried amortised cost using effective interest rate method availableforsale financial assets subsequently carried fair value unrealised changes fair value recorded equity availableforsale financial assets sold impaired otherwise disposed cumulative gains losses previously recognised equity included financial income current period financial assets originated group subsequently carried amortised cost financial assets assessed possible impairment balance sheet date impairment charge recorded objective evidence impairment issuer bankruptcy default significant financial difficulty availableforsale financial assets market value original cost net previous impairment sustained sixmonth period considered impaired decreases market price less original cost net previous impairment less sustained sixmonth period considered objective evidence impairment movements fair value recorded equity objective evidence impairment asset sold otherwise disposed financial assets carried amortised cost impairment charge difference carrying value recoverable amount calculated using estimated future cash flows discounted using original effective interest rate availableforsale financial assets impairment charge amount currently carried equity difference original cost net previous impairment fair value derivatives derivative financial instruments initially recorded cost including transaction costs derivatives subsequently carried fair value apart derivatives designated qualifying cash flow hedging instruments see changes fair value recorded financial income period arise embedded derivatives recognised separately closely related host contract hedging purposes hedge accounting hedging relationships may three types fair value hedges hedges particular risks may change fair value recognised asset liability cash flow hedges hedges particular risks may change amount timing future cash flows hedges net investment foreign entity hedges particular risks may change carrying value net assets foreign entity annual report notes roche group consolidated financial statements qualify hedge accounting hedging relationship must meet several strict conditions documentation probability occurrence hedge effectiveness reliability measurement conditions met relationship qualify hedge accounting case hedging instrument hedged item reported independently hedging relationship particular derivatives reported fair value changes fair value included financial income qualifying fair value hedges hedging instrument recorded fair value hedged item recorded previous carrying value adjusted changes fair value attributable hedged risk changes fair values reported financial income qualifying cash flow hedges hedging instrument recorded fair value portion change fair value effective hedge included equity remaining ineffective portion reported financial income hedging relationship hedge firm commitment highly probable forecasted transaction cumulative changes fair value hedging instrument recorded equity included initial carrying value asset liability time recognised qualifying cash flow hedges cumulative changes fair value hedging instrument recorded equity included financial income time forecasted transaction affects net income qualifying hedges net investment foreign entity hedging instrument recorded fair value portion change fair value effective hedge included equity remaining ineffective portion recorded financial income hedging instrument derivative equity cases entity disposed cumulative changes fair value hedging instrument recorded equity included financial income time disposal changes accounting policy significant changes accounting policy periods presented international financial reporting standards revised new standards interpretations became effective january asignificant effect groups financial statements late international accounting standards board iasb published revised version ias financial instruments disclosure presentation revised version ias financial instruments recognition measurement improvements international accounting standards makes changes existing standards first quarter iasb published ifrs sharebased payment ifrs business combinations ifrs insurance contracts ifrs noncurrent assets held sale discontinued operations revised versions ias impairment assets ias intangible assets amendments ias group adopt effective january group estimates significant effects groups results come implementation ifrs ifrs ifrs sharebased payment amongst matters new standard requires fair value equity compensation plans awarded employees estimated grant date recorded expense vesting period currently plans equitysettled recorded equity case genentech chugai plans balance sheet minority interests standard also requires retrospective application within certain transitional restrictions based initial work carried applying transitional restrictions group estimates pretax expense would approximately million swiss francs million swiss francs relate genentechs equity compensation plans seenote million swiss francs relate roche option plan see note due impact transitional arrangements amount indicative future expenses plans information groups equity compensation plans given notes new standard also affect groups effective tax rate deferred tax recorded based expected tax benefits arising vested awards using current equity price input calculation therefore deferred tax benefit recorded particular period sensitive current equity price whereas pretax expense fixed reference equity price grant date sensitive current annual report notes roche group consolidated financial statements equity price impact income statement deferred tax benefit capped reference ifrspretax expense excess recognised directly equity based initial work carried applying transitional restrictions group estimates tax benefit would approximately million swiss francs aftertax additional expense million swiss francs million swiss francs would attributable minorities leaving estimated impact net income million swiss francs ifrs business combinations amongst matters new standard requires amortisation goodwill cease date implementation goodwill continue tested impairment standard requires prospective application standard applied goodwill amortisation expenses million swiss francs would recorded additional impairment would necessary inaddition together ias revised intangible assets standard typically result intangible assets recognised acquisitions previously consequently less goodwill arise new standard also affect groups effective tax rate currently tax benefit recorded respect goodwill amortisation based groups results groups effective tax rate expected reduce two three percentage points ias revised intangible assetsamongst matters revised standard typically result intangible assets recognised inlicensing arrangements similar research development alliances previously expenditure would recorded research development expenses revised standard requires prospective application ias revised presentation financial statements amongst matters revised standard require minority interests included part groups equity separate category balance sheet increase groups equity million swiss francs effective january group expect new revised standards significant effect groups results financial position group draws attention fact already fully applies existing iason financial instruments done since financial risk management group exposed various financial risks arising group 's underlying operations corporate finance activities financial risks group exposed predominantly related changes foreign exchange rates interest rates equity prices well creditworthiness solvency group 's counterparties groups subsidiaries genentech chugai treasury operations operational independence whilst working within financial risk management framework consistent rest group information financial risks available annual reports chugai genentech financial risk management within group governed policies guidelines approved senior management policies guidelines cover foreign exchange risk interest rate risk market risk credit risk liquidity risk group policies guidelines also cover areas cash management investment excess funds raising short longterm debt compliance policies guidelines overseen segregated functions within group objective financial risk management contain deemed appropriate exposures various types financial risks mentioned order limit negative impact groups financial income balance sheet group actively measures monitors manages financial risk exposures various functions pursuant segregation duties principles annual report notes roche group consolidated financial statements accordance financial risk policies group manages market risk exposures deemed appropriate use financial instruments derivatives groups policy practice enter derivatives transactions trading speculative purposes purposes unrelated underlying business foreign exchange risk group operates across world exposed movements foreign currencies affecting net income financial position expressed swiss francs group actively monitors currency exposures appropriate enters transactions aim preserving value assets commitments anticipated transactions group uses forward contracts foreign exchange options crosscurrency swaps hedge certain committed anticipated foreign exchange flows financing transactions well net investments transaction exposure arises amount local currency paid received transactions denominated foreign currencies may vary due changes exchange rates many group companies income primarily local currency significant amount expenditure especially purchase goods resale interest repayment loans foreign currencies similarly transaction exposure arises net balances monetary assets held foreign currencies local level group companies manage exposure necessary means financial instruments options forward contracts addition group treasury monitors total worldwide exposure help comprehensive data received monthly basis translation exposurearises consolidation foreign currency denominated financial statements groups foreign subsidiaries effect groups consolidated equity shown currency translation movement group partially hedges net investments foreign currencies taking foreign currency loans issuing foreign currency denominated debt instruments major translation exposures monitored regular basis significant part groups cash outflows research development production administration denominated swiss francs much smaller proportion groups cash inflows swiss franc denominated result increase value swiss franc relative currencies adverse impact consolidated net income similarly relative fall value swiss franc favourable effect results published swiss francs interest rate risk interest rate risk arises movements interest rates could effects groups net income financial position changes interest rates cause variations interest income expenses interest bearing assets liabilities addition affect market value certain financial assets liabilities instruments described following section market risk interest rates groups major debt instruments fixed described note group uses interest rate derivatives manage interest raterisk market risk financial assets changes market value certain financial assets derivative instruments affect net income financial position group financial longterm assets held strategic purposes marketable securities held fund management purposes risk loss value managed reviews prior investing continuous monitoring performance investments changes risk profile investments equities bonds debentures fixed income instruments entered basis guidelines regard liquidity credit rating annual report notes roche group consolidated financial statements credit risk credit risk arises possibility counterparty transaction may unable unwilling meet obligations causing financial loss group trade receivables subject policy active risk management focussing assessment country risk credit availability ongoing credit evaluation account monitoring procedures significant concentrations within trade receivables counterparty credit risk due groups large number customers wide geographical spread credit exposures critical countries group entered respective credit insurance country risk limits exposures continuously monitored exposure financial assets credit risk controlled setting policy limiting credit exposure highquality counterparties regular reviews credit ratings setting defined limits individual counterparty appropriate reduce exposure netting agreements isda international swaps derivatives association master agreement signed respective counterparties maximum exposure credit risk resulting financial activities without considering netting agreements equal carrying amount financial assets credit exposure diversified amongst different counterparties liquidity risk group companies need sufficient availability cash meet obligations individual companies responsible cash management including shortterm investment cash surpluses raising loans cover cash deficits subject guidance group certain cases approval group level group maintains sufficient reserves cash readily realisable marketable securities meet liquidity requirements times addition strong international creditworthiness group allows tomake efficient use international capital markets financing purposes changes group organisation listing major group subsidiaries associated companies included note gains losses changes group organisationin millions chf consumer health otc business gain loss disposal consumer health otc business gain loss disposal attributable roche prescription business vitamins fine chemicals business impairment net assets gain loss disposal total disposal consumer health otc business discussed note disposal vitamins fine chemicals business discussed note igen february group acquired controlling interest igen international inc igen public company headquartered gaithersburg maryland usa acquisition gives group broad access human invitro diagnostics immunochemistry sector use electrochemiluminiscence ecl technology development elecsys product line acquisition approved extraordinary general meeting igens shareholders february cleared relevant antitrust authorities thetotal cash consideration paid million swiss francs incidental costs million swiss francs addition accumulated losses million swiss francs recorded equity hedging thistransaction removed equity included part acquisition cost allocation total purchase consideration million swiss francs follows annual report notes roche group consolidated financial statements igen acquisition net assets acquiredin millions chf goodwill intangible assets deferred income taxes cash net assets liabilities total goodwill acquired intangible assets amortised straightline basis years beginning march igen acquisition impact operating profitin millions chf royalty expenses preacquisition amortisation intangible assets effect operating profit exceptional items goodwill amortisation effect operating profit disetronic effective may group acquired controlling interest disetronic public company headquartered burgdorf switzerland disetronic world leader research development commercialisation insulin pumps injection systems treatment diabetes disetronics infusion systems division become part roche diagnostics diabetes care business area part acquisition process disetronics injection systems simultaneously resold disetronics founder chairman continues operate independent company group interest disetronic acquisition approved extraordinary general meeting disetronics shareholders april subsequently cleared relevant antitrust authorities group paid shareholders disetronic swiss francs cash two roche nonvoting equity securities disetronic share net consideration paid million swiss francs million swiss francs cash million swiss francs form roche nonvoting equity securities addition incidental costs million swiss francs cash flows changes group organisationin millions chf acquisitions igen disetronic acquisitions total cash flows acquisitions subsidiaries associated companies divestments consumer health otc business vitamins fine chemicals business divestments total cash flows divestments subsidiaries associated companies amounts net cash balances acquireddivested companybusiness include cash outflows incidental transaction costs annual report notes roche group consolidated financial statements segment information information business segment millions chf roche genentech chugai total prescription prescription prescription pharmaceuticals segment revenues segment revenue divisional sales less interdivisional sales divisional sales third parties operating profit exceptional items amortisation goodwill major legal cases changes group organisation segment results operating profit segment assets liabilities divisional assets segment assets segment assets nonsegment assets total assets divisional liabilities segment liabilities segment liabilities nonsegment liabilities total liabilities segment information capital expenditure depreciation amortisation intangible assets impairment longterm assets restructuring expenses research development costs income associated companies investments associated companies number employees chugai prescription results include million swiss francs writeoff fair value adjustment inventories arising acquisition accounting chugai see note fair value adjustments written line inventory turnover fully written end first quarter consumer health otc shown discontinuing business see note segment results exclude total million swiss francs million swiss francs administration costs previously allocated consumer health otc business groups published segment results items transferred sale business therefore reclassified business segment others within groups continuing business results annual report notes roche group consolidated financial statements continuing consumer health vitamins diagnostics others businesses otc fine chemicals group vitamins fine chemicals shown discontinuing business see note business sold effective september results include impairment charge million swiss francs net assets vitamins fine chemicals business others includes costs corporate headquarters well nonallocated administration costs referred group reassessing latter view reducing restructuring annual report notes roche group consolidated financial statements information geographical segmentin millions chf sales third parties destination segment assets capital expenditure switzerland european union rest europe europe north america latin america japan rest asia asia africa australia oceania segment total nonsegment assets consolidated total switzerland european union rest europe europe north america latin america japan rest asia asia africa australia oceania segment total nonsegment assets consolidated total genentech effective september group acquired majority interest approximately genentech inc biotechnology company united states june group exercised option acquire remaining shares genentech june point genentech became owned subsidiary group july october march group completed public offerings genentechs common stock result groups majority interest genentech issues additional shares common stock connection equity compensation plans also may issue additional shares purposes affiliation agreement group genentech provides amongst things genentech establish stock repurchase programme maintain groups percentage ownership interest genentech annual report notes roche group consolidated financial statements groups ownership genentech decreased due conversion redemption lyons iv us dollar exchangeable notes described note changes groups ownership also arose stock repurchases genentech exercise stock options genentech employees effective april genentech implemented twoforone share split genentechs common stock form stock dividend impact either groups percentage ownership genentech groups consolidated results december groups interest genentech genentech prescription shown separate business segment segment information common stock genentech publicly traded listed new york stock exchange symbol dna genentech prepares financial statements conformity accounting principles generally accepted united states us gaap filed quarterly basis us securities exchange commission sec differences ifrs us gaap due certain consolidation entries differences requirements international financial reporting standards ifrs us gaap differences genentechs standalone results us gaap basis results genentech consolidated roche group accordance ifrs reconciliation genentech results usd chf usd chf millions millions millions millions operating margin us gaap basis redemption costs special litigation items operating margin nonus gaap basis add deduct differences consolidation entries add back redemption costs differences consolidation entries operating profit exceptional items ifrs basis add deduct exceptional items amortisation goodwill major legal cases segment resultoperating profit ifrs basis add deduct nonoperating items ifrs basis financial income income taxes net income ifrs basis minority interest percentage average year income applicable minority interest ifrs basis translated usd chf usd chf annual report notes roche group consolidated financial statements following acquisition group interest genentech june analysis carried acquisition accounting identified amounts attributable inprocess research development iprd genentechs us gaap financial statements items recorded either adjustment equity onetime expense ifrs items classified separate assets date acquisition therefore form part goodwill therefore years subsequent goodwill amortisation expense respect iprd groups results ifrs genentech adopted us accounting standards fas fas effective january goodwill longer amortised subject impairment test least annually ifrs goodwill continues amortised also subject testing impairment effective january group implement ifrs business combinations date goodwill longer amortised differences ifrs us gaap relatively minor impact genentech stock repurchases stock options september genentechs board directors authorised extension current stock repurchase programme repurchase million us dollars genentechs common stock december previously december genentechs board directors authorised stock repurchase programme repurchase million us dollars genentechs common stock genentech repurchased common stock worth million us dollars million swiss francs million us dollars million swiss francs genentech employee stock purchase programme allows employees purchase genentechs common stock lower market value grant date purchase date thousand shares genentech common stock purchased resulting cash inflow million swiss francs genentech also stock option plan adopted amended april genentechs shareholders approved equity incentive plan plans allow granting various stock options incentive stock options stock purchase rights shares employees directors consultants genentech incentive stock options stock purchase rights granted plan date details stock options shown table restated effects twoforone share split genentech stock options number options thousands outstanding january granted exercised cancellations outstanding end year exercisable terms options outstanding december options outstanding options exercisable weighted weighted number weighted average average number average outstanding years remaining exercise exercisable exercise range exercise prices usd thousands contractual life price usd thousands price usd total annual report notes roche group consolidated financial statements genentech granted thousand options average exercise price usd options vest fouryear period expire fair value options granted estimated using binomial model million swiss francs options exercised average exercise price ofusd cash inflow equivalent million swiss francs net accounting effect genentech stock repurchases stock options recorded minority interests seenote effective january group implement ifrs sharebased payment amongst matters new standard requires value equitysettled plans genentech stock option plans employee stock purchase programme estimated grant date recorded employee remuneration expense vesting period example fair value million swiss francs options granted would recorded expense subsequent fouryear vesting period based initial work carried applying transitional restrictions group estimates pretax expense genentechs equity compensation plans would approximately million swiss francs due impact transitional arrangements amount indicative future expenses plans see also note matters discussed note group recorded income million swiss francs respect certain litigation matters genentech chugai effective october roche group chugai completed alliance create leading researchdriven japanese pharmaceutical company formed merger chugai roches japanese pharmaceuticals subsidiary nippon roche merged company known chugai fully consolidated subsidiary group december groups interest chugai chugai prescription shown separate business segment segment information results chugais otc business included consumer health otc business segment segment information given note common stock chugai publicly traded listed tokyo stock exchange chugai prepares financial statements conformity accounting principles generally accepted japan jgaap filed quarterly basis tokyo stock exchange differences ifrs jgaap due certain consolidation entries differences requirements international financial reporting standards ifrs jgaap differences chugais standalone results jgaap basis results chugai consolidated roche group accordance ifrs acquiring roche chugai treated acquisition ifrs jgaap alliance treated merger chugai nippon roche therefore jgaap results chugai include goodwill fair value adjustments recorded roches results quantified table moreover acquisition accounting includes roches fair value adjustments therefore impact net income needs added back minority interest calculations roches ifrs results roches ifrs results depreciation property plant equipment calculated using straightline method chugais jgaap results reducing balance method used additionally certain income expenses notably restructuring costs required jgaap reported extraordinary items chugais jgaap results extraordinary items reported operating profit line roches ifrs results items normally included part operating profit treated extraordinary exceptional items restructuring costs million swiss francs million swiss francs differences ifrs jgaap relatively minor impact annual report notes roche group consolidated financial statements reconciliation chugai prescription resultsin millions chf chugai prescription operating profit exceptional items acquisition accounting impacts ifrs basis writeoff fair value adjustments inventories depreciation property plant equipment amortisation acquisitionrelated intangible assets chugai prescription operating profit exceptional items ifrs basis add deduct exceptional items amortisation goodwill chugai prescription segment resultoperating profit ifrs basis add deduct chugai otcand nonoperating items ifrs basis financial income chugai otc income taxes net income ifrs basis minority interest calculation add back acquisition accounting impact net income net income excluding acquisition accounting minority interest percentage average year income applicable minority interest ifrs basis translated jpy chf jpy chf dividends dividends distributed thirdparties holding chugai shares totalled million japanese yen million swiss francs million japanese yen million swiss francs recorded minority interests see note dividends paid chugai roche eliminated consolidation intercompany items chugai otc july chugai announced sale otc business lion corporation sale completed effective december pretax gain disposal million swiss francs recorded early retirement programme may chugai announced early retirement programme retirement date september end application period august total employees applied programme restructuring costs billion japanese yen million swiss francs recorded programme share repurchase chugai repurchased common shares total consideration billion japanese yen million swiss francs result groups ownership chugai increased net accounting effect chugai share repurchases recorded minority interests see note annual report notes roche group consolidated financial statements chugai convertible bonds details series chugai pharmaceutical unsecured convertible bonds including conversions year given note stock acquisition rights chugai adopted stock acquisition rights programme programme allows granting rights employees directors chugai right entitles holder purchase chugai shares aspecified exercise price chugai stock acquisition rights number rights outstanding january granted exercised cancellations outstanding end year exercisable terms rights outstanding december rights outstanding rights exercisable number remaining exercise number exercise year grant outstanding contractual life price jpy exercisable price jpy years years chugai granted rights exercise price jpy rights vested immediately expire fair value rights granted estimated using binomial model million swiss francs effective january group implement ifrs sharebased payment amongst matters new standard requires value equitysettled plans chugai stock acquisition rights estimated grant date recorded expense vesting period see also note consumer health otc business july group announced sale roche consumer health global otc overthecounter medicines business bayer group sale also included five production facilities belonging roche prescription business agreement bayer majority local businesses transferred bayer end smaller markets transaction yet closed completion expected within first half december divestment bayer completed measured terms roche consumer health sales third parties july chugai announced sale otc business lion corporation sale completed effective december annual report notes roche group consolidated financial statements gain disposal consumer health otc business five roche prescription production facilities december millions chf consideration less net debt adjustments less purchase price adjustment mechanisms net proceeds cash receivable bayer collected january incidental transaction costs net assets consumer health otc business five production facilities property plant equipment goodwill intangible assets inventories accounts receivable cash provisions accounts payable net assets liabilities accumulated currency translation adjustments impairment restructuring charges accruals residual obligations retained roche group gain disposal discontinuing businesses consumer health otc business segment continuing businesses roche prescription business segment table includes preliminary assessments net debt adjustments purchase price mechanisms well initial calculations impairment restructuring charges accruals residual obligations retained roche group final assessments calculations made preliminary assessment disposal results tax expense currently estimated million swiss francs aftertax gain million swiss francs million swiss francs attributable minority interests giving net income million swiss francs disposal cash inflow disposal net cash balances million swiss francs held companies within consumer health otc business cash payments transaction costs million swiss francs million swiss francs terms agreement majority cash proceeds totalling million swiss francs transferred group january amount shown receivable december balance sheet discontinuing businesses consumer health otc business segment consumer health otc business shown discontinuing operation consolidated results represents separate major line business distinguished operationally financial reporting purposes results consumer health otc business segment shown note annual report notes roche group consolidated financial statements consumer health otc business amounts included income statementin millions chf sales third parties expenses operating profit exceptional items amortisation goodwill major legal cases changes group organisation operating profit result associated companies financial income profit taxes income taxes profit taxes minority interests net income figures exclude total million swiss francs million swiss francs administration overheads previously allocated consumer health otc business groups published segment results items transferred sale business therefore reclassified business segment others within groups continuing business results group reassessing view reducing restructuring consumer health otc business amounts included balance sheetin millions chf december december property plant equipment longterm assets current assets total assets longterm debt provisions current liabilities total liabilities net assets significant operating cash flows consumer health otc business million swiss francs million swiss francs arise operating profit exceptional items depreciation amortisation impairment significant investing financing cash flows consumer health otc business continuing businesses roche prescription business segment five production facilities included sale bayer shown part roche prescription results date disposal five production facilities transferred bayer end therefore included december balance sheet connection divestment roche consumer health roche prescription business reassessed utilisation manufacturing facilities infrastructure service capacities addition terms agreement bayer roche prescription business agreed certain interim manufacturing service obligations bayer result roche prescription business recorded impairment charge based estimated net selling price shown table annual report notes roche group consolidated financial statements bayer transaction impact roche prescription business segment millions chf net proceeds incidental transaction costs net assets five production facilities impairment charges restructuring charges accruals residual obligations retained roche prescription business gain loss disposal roche prescription business segment july separate transaction roche prescription business announced granted glaxosmithkline consumer healthcare exclusive license us nonprescription rights antiobesity drug orlistat marketed roche prescription medicine brand name xenical agreement provides upfront payment million us dollars million swiss francs additional payments achievement agreed milestones royalties upfront payment received initially reported deferred income recognised income earned period development collaboration group retains rights market xenical prescription drug us rights prescription nonprescription outside us vitamins fine chemicals business effective september receiving final regulatory approvals group completed sale global vitamins fine chemicals business vfc business dutch company dsm impairment charge million swiss francs recorded june based assessments respective dates difference expected net proceeds disposal net assets vfc business taking account residual obligations retained roche group preliminary assessment made showed additional loss disposal million swiss francs arose disposal vfc business final assessment expected finalised following review approval group dsm implementation purchase price adjustment mechanisms based current status review approval process adjustments preliminary estimate loss disposal made gain loss disposal vitamins fine chemicals businessin millions chf consideration less net debt adjustment less purchase price adjustment mechanisms net proceeds dsm received cash dsm shares incidental transaction costs net assets vfc business net impairment charges accruals residual obligations retained roche group gain loss disposal preliminary assessment disposal resulted tax benefit million swiss francs cash inflow disposal net cash balances million swiss francs held companies within vfc business million swiss francs following sale vfc business certain assets liabilities vitamins fine chemicals division mainly associated vitamin case remain group described section vitamin case addition group given dsm certain indemnities respect remedial actions annual report notes roche group consolidated financial statements sites vfc business may required environmental laws arrangements put place regarding utilisation certain assets certain purchasing contracts well adopting dsm preferred supplier pharmaceutical ingredients one arrangements group guaranteed purchase period four years beginning january products sales value totalling million euros group reimburse dsm unutilised amounts arrangements consist certain residual obligations fully accrued vitamins fine chemicals division shown discontinuing operation consolidated results results vfc business sold dsm included consolidated results group sale september results vitamins fine chemicals business segment shown note vfc business amounts included income statementin millions chf vitamin case vitamins fine vfc business residual chemicals sold dsm amounts business sales third parties expenses operating profit exceptional items amortisation goodwill major legal cases changes group organisation operating profit result associated companies financial income profit taxes income taxes profit taxes minority interests net income remaining segment liabilities vfc business shown note consist primarily provisions related vitamin case matters transferred dsm addition vitamin case payments cash flows vfc business nine months prior sale dsm consisted operating cash flow million swiss francs financing cash outflows million swiss francs investing cash outflows million swiss francs vitamin case following settlement agreement us department justice may regarding pricing practices vitamin market overall settlement agreement class action suit brought us buyers bulk vitamins group recorded provisions respect vitamin case provisions groups best estimate time total liability may arise taking account currency movements time value money provisions legal fees recorded separately december december based development litigation recent settlement negotiations group recorded additional provisions million swiss francs respectively january district columbia circuit court appeals ruled nonus plaintiffs may bring claims us courts us antitrust laws alleged damages suffered transactions outside united states connection vitamin case june supreme court united states nullified decision district columbia circuit court appeals class action litigation brought behalf nonus purchasers bulk vitamins roche manufacturers addition nullification annual report notes roche group consolidated financial statements decision lower court supreme court remanded case lower court review alternative arguments might permit claims proceed us district columbia circuit court appeals asked parties submit written briefs oral hearing scheduled april provisions recorded respect litigation eventual outcome uncertain stage total payments year million swiss francs million swiss francs charged provisions previously recorded payments made include million us dollars million swiss francs direct customers united states group seeking resolve remaining outstanding issues however timing final amounts involved uncertain remaining provisions recorded total million swiss francs based current litigation recent settlement agreements provisions considered shortterm cash outflows expected arise discounted time value money considered material case litigation negotiations progress possible ultimate liability may different amount provisions currently recorded part disposal process liabilities respect vitamin case discussed remain roche group roche dsm signed indemnity cooperation agreement roche may provide dsm certain indemnities guarantees connection vitamin case major legal cases income expenses major legal casesin millions chf igen litigation writeoff intangible assets release provisions genentech legal cases receipts payments settlements total income expense igen litigation february united states district court maryland entered judgement civil litigation roche diagnostics gmbh germany rdg igen international inc igen claims related licensing igens electrochemiluminescence ecl technology rdg court concluded several breaches licence agreement material igen right terminate licence agreement awarded igen million us dollars compensatory damages million us dollars punitive damages july united states court appeals fourth circuit reversed substantial damages awarded rdg court reversed finding rdg engaged unfair competition continuation patent lawsuit igen one rdgs affiliated companies setting aside claim court eliminated basis award million us dollars punitive damages rdg court also held rdg violate implied covenant good faith fair dealing license agreement thereby also setting aside award million us dollars compensatory damages claim total court eliminated million us dollars million us dollars judgement entered rdg court left intact jurys award remaining damages finding igen may terminate license agreement rdg igen notified rdg igen terminate license agreement july group igen announced plans group acquire igen acquisition completed effective february see note previous license agreement terminated group wrote intangible assets technology recorded time acquisition corange group roche group net book value million swiss francs time group released income million swiss francs litigation provisions balance provision less remaining outstanding compensatory damages awards net two amounts expense totalling million swiss francs recorded expense major legal cases results annual report notes roche group consolidated financial statements march rdg paid million us dollars collateral deposit account relation igen litigation following entry final judgement rdg paid remaining million us dollars million swiss francs respect remaining compensatory damages igen amount collateral deposit account repaid group net cash inflow two transactions million swiss francs genentech legal cases group recorded income million swiss francs respect certain litigation settlements including litigation involving amgen june genentech announced los angeles county superior court jury voted award city hope medical center approximately million us dollars compensatory damages based finding breach agreement genentech city hope june jury voted award city hope million us dollars punitive damages case september genentech filed notice appeal jury verdict damages awards california court appeal october court appeal affirmed verdict damages awards respects also october genentech announced seek review california supreme court discretion cases review november genentech filed petition review california supreme court city hope filed answer december genentech filed reply december california supreme court yet ruled petition full provision classified shortterm recorded damages awards appeals process interest accrues total amount damages simple annual rate following judgement interest million swiss francs million swiss francs recorded time cost provisions within interest expenses see note october genentech entered arrangement third party insurance companies post surety bond million us dollars connection judgement part arrangement genentech pledged million us dollars cash investments secure bond increased million us dollars million us dollars million swiss francs amount reported restricted cash within current assets see note addition genentech party patent infringement suit filed chiron corporation june us district court eastern district california sacramento respect herceptin june court issued several decisions regarding summary judgement motions filed jury trial suit began august following first phase trial based findings jury court entered judgement favour genentech november chiron filed notice appeal us court appeals federal circuit december genentech filed notice crossappeal court april genentech announced us court appeals federal circuit unanimously affirmed judgement us district court eastern district california sacramento found favour genentech chiron filed petition rehearing court appeals motion subsequently denied october chiron filed petition united states supreme court seeking review judgment favour genentech january supreme court announced denied review judgment august united states patent trademark office declared interference chiron patent involved lawsuit patent application exclusively licensed genentech university pennsylvania relating antiher antibodies declaring interference patent office determined substantial question whether inventors chiron patent first invent technology involved entitled patent subsequently patent office redeclared interference include addition abovereferenced chiron patent university patent application number patents patent applications owned either chiron genentech including chiron patent also issue second patent infringement lawsuit filed march genentech chiron november patent office issued rulings several preliminary motions rulings terminated interferences involving patent application referenced genentech licensed university redeclared interferences genentech chiron patents patent applications made several determinations could affect validity genentech chiron patents patent applications involved remaining interferences interference proceedings ongoing including possibility rulings preliminary motions challenged appealed therefore outcome matter annual report notes roche group consolidated financial statements determined time connection second patent infringement lawsuit filed march genentech chiron discovery case currently stayed january arbitration proceedings began genentech tanox biosystems inc tanox regarding july settlement crosslicensing agreement relating development manufacture certain antibody products directed towards immunoglobin e including xolair hu tanox claimed breaches agreement genentech made counterclaims february genentech announced agreement reached tanox genentech novartis settled litigation parties finalised detailed terms threeparty collaboration part settlement genentech novartis reimbursed tanox million us dollars portion development costs august genentech amgen inc announced settlement patent litigation us district court northern district california settlement agreement parties agreed dismiss claims counterclaims part settlement amgen made onetime payment genentech november genentech bayer settled breachofcontract action genentech brought bayer relating bayers manufacture sale factor viii license agreement bayer genentech part settlement bayer made onetime payment genentech income major legal cases million swiss francs recorded results respect settlements october genentech received subpoena united states department justice requesting documents related promotion rituxan prescription product approved treatment relapsed refractory lowgrade follicular cd positive bcell nonhodgkins lymphoma genentech cooperating associated investigation genentech advised civil criminal nature potential outcome matter determined time genentechs annual report quarterly sec filings contain detailed disclosures litigation matters required us gaap include details matters well including information litigation currently significant matters referred employee benefits employee remunerationin millions chf wages salaries social security costs postemployment benefits defined benefit plans postemployment benefits defined contribution plans employee benefits total employees remuneration charges employee benefits included relevant expenditure line function number employees yearend employee benefits consist mainly life insurance schemes certain insurance schemes providing medical cover well long shortterm disability benefits pensions postemployment benefits employees covered retirement benefit plans sponsored group companies nature plans varies according legal regulations fiscal requirements economic conditions countries employees employed major plans defined benefit plans largest located switzerland united states germany united kingdom japan postemployment benefits consist mostly postretirement healthcare life insurance schemes principally united states plans usually funded payments group employees trusts independent groups finances plan unfunded notably major defined benefit plans germany liability obligation recorded groups balance sheet annual report notes roche group consolidated financial statements defined benefit plans expenses recognisedin millions chf current service cost interest cost expected return plan assets net actuarial gains losses recognised past service cost gains losses curtailment total included employees remuneration actual return plan assets million swiss francs million swiss francs december group paid additional contribution million swiss francs one swiss post employment defined benefit plans payment included contributions paid table accounted part recognised surplus funded pension plans groups consolidated financial statements thereafter included actuarial calculation groups pension expenses balances defined benefit plans movements recognised net asset liabilityin millions chf beginning year disetronic consumer health otc business vitamins fine chemicals business total expenses included employees remuneration contributions paid benefits paid unfunded plans currency translation effects end year defined benefit plans amounts recognised balance sheetin millions chf funded plans actuarial present value funded obligations due past present employees plan assets held trusts fair value plan assets excess deficit actuarial present value funded obligations unrecognised actuarial gains losses unrecognised past service costs net recognised asset liability funded obligations due past present employees unfunded plans actuarial present value funded obligations due past present employees unrecognised actuarial gains losses unrecognised past service costs recognised liability actuarial present value unfunded obligations due past present employees total recognised asset liability funded unfunded obligations due past present employees reported surplus recognised longterm asset deficit recognised noncurrent liability total net asset liability recognised annual report notes roche group consolidated financial statements amounts include nonpension postemployment benefit schemes principally medical plans shown postemployment benefit plansin millions chf actuarial present value obligations due past present employees plan assets held trusts fair value plan assets excess deficit actuarial present value funded obligations less unrecognised actuarial gains losses net recognised asset liability amounts recognised balance sheet postemployment defined benefit plans predominantly non current reported longterm assets noncurrent liabilities plan assets funded plans include groups equity instruments group operates defined benefit schemes many countries actuarial assumptions vary based upon local economic social conditions range assumptions used actuarial valuations significant defined benefit plans countries stable currencies interest rates shown defined benefit plans actuarial assumptions weighted weighted average range average range discount rates projected rates remuneration growth expected rates return plan assets healthcare cost trend rate employee stock options equity compensation benefits roche option plan group offers nonvoting equity security options certain directors management exercise price market price nonvoting equity securities date issue options non tradable sevenyear duration vest phased basis three years group covers obligations purchasing nonvoting equity securities derivatives thereon see note cost instruments reported equity instruments within equity balance sheet options exercised cash received credited equity instruments impacts income statement employer social insurance costs administrative costs plan previous option compensation plan whereby group purchased options directly thirdparty financial institutions granted certain employees closed options granted details roche option plan shown table roche option plan number options outstanding january granted exercised cancellations outstanding end year exercisable annual report notes roche group consolidated financial statements terms options outstanding december options outstanding options exercisable weighted weighted weighted average average average number years remaining exercise number exercise year grant outstanding contractual life price chf exercisable price chf total group granted options average exercise price chf options vest threeyear period expire fair value options granted estimated using binomial model million swiss francs options exercised average exercise price chf cash inflow equivalent million swiss francs effective january group implement ifrs sharebased payment amongst matters new standard requires value equitysettled plans roche option plan estimated grant date recorded expense vesting period see also note roche performance share plan group offered future nonvoting equity security awards boards discretion cash equivalent certain directors key senior managers programme established beginning effect three years amount nonvoting equity securities granted depended upon individuals salary level achievement performance targets linked groups total shareholders return shares nonvoting equity securities combined relative groups peers threeyear period date grant discretion board directors plan concluded end non voting equity securities vested fair value million swiss francs allocated recipients blackout period ended cost plan accrued vesting period grant based final fair value award estimated balance sheet date year cost plan million swiss francs million swiss francs reported within relevant operating expense categories board approved new threeyear cycle roche performance share plan operate roche connect programme enables employees worldwide except united states certain countries make regular deductions salaries purchase nonvoting equity securities administered independent third parties group makes contribution programme allows employees purchase nonvoting equity securities discount usually administrator purchases necessary nonvoting equity securities directly market nonvoting equity securities held december programme operational since october year cost plan million swiss francs million swiss francs reported within relevant operating expense categories stock appreciation rights employees certain north american subsidiaries group receive stock appreciation rights sars part compensation sars may exercised vesting period one three years cash payment based upon amount market price groups american depositary receipts adrs point exercise exceeds strike price grant price issuance annual report notes roche group consolidated financial statements stock appreciation rights number rights outstanding january granted exercised cancellations outstanding end year exercisable amounts recorded consolidated financial statements expense millions chf accrual millions chf terms rights outstanding december rights outstanding rights exercisable weighted weighted average average number exercise number exercise year grant outstanding expiry price usd exercisable price usd award award award award total group granted rights average exercise price usd rights vest threeyear period expire fair value rights granted estimated using binomial model million swiss francs rights exercised average exercise price usd cash outflow equivalent million swiss francs following approval roche global longterm incentive programme see group future plan award cashsettled sars based market price adrs roche global longterm incentive programme board approved new global longterm incentive programme onwards available certain directors management employees selected discretion group programme consist stocksettled stock appreciation rights ssars group alternative granting awards existing roche option plan ssars give employees right receive nonvoting equity securities reflecting value appreciation market price nonvoting equity securities grant date exercise date group would cover obligations purchasing nonvoting equity securities derivatives thereon genentech chugai plans genentech stock option plan discussed note chugai stock acquisition rights programme discussed note annual report notes roche group consolidated financial statements operating income operating incomein millions chf royalty income gains disposal products total operating income part continuous realignment product portfolio group periodically disposes product lines longer considered core products priorities within product development portfolio proceeds reinvested groups inlicensing arrangements research development alliances collaborations february group announced sale exclusive us rights soriatane connetics corporation cash received million swiss francs august group agreed license sell certain patent rights patent portfolio third party cash received million swiss francs september group announced sale protein design labs pdl business related zenapax product worldwide disease indications organ transplantation group continue market zenapax transplantation indications point pdl option purchase cash received million swiss francs group pdl signed separate agreement co develop commercialise zenapax asthma related respiratory diseases disposals products concerned book value gain disposal cash proceeds disposals reported within operating profit roche prescription segment operating expenses operating expensesin millions chf royalty expenses restructuring expenses impairment property plant equipment impairment intangible assets stock appreciation rights total operating expenses annual report notes roche group consolidated financial statements financial income financial incomein millions chf gains sale equity securities losses sale equity securities dividend income gains losses equity derivatives net writedowns impairments equity securities net income equity securities interest income gains sale debt securities losses sale debt securities writedowns impairments longterm loans net interest income income debt securities interest expense amortisation discount debt instruments gains losses interest rate derivatives net time cost provisions net interest expense foreign exchange gains losses net gains losses foreign currency derivatives net net foreign exchange gains losses net financial income expense total net financial income exceptional income bond conversion redemption group converted redeemed certain debt instruments debt reduced million swiss francs total cash outflow million swiss francs net pretax gain million swiss francs resulted shown net gain reported exceptional item due materiality gain order fairly present groups results details given note impact bond conversion redemptionin millions chf exceptional income bond conversion increase redemption reduction pretax debt cash outflow lyons iv us dollar exchangeable notes lyons iii us dollar exchangeable notes chameleon us dollar bonds lyons v us dollar exchangeable notes limited conversion preferred stock total annual report notes roche group consolidated financial statements income taxes income tax expensesin millions chf current income taxes adjustments recognised current tax prior periods deferred income taxes total charge income taxes since group operates across world subject income taxes many different tax jurisdictions group calculates average expected tax rate weighted average tax rates tax jurisdictions group operates within groups average expected tax rate increasing significance genentech chugai causes increase rate offset ongoing improvement groups structures groups effective tax rate reconciled groups average expected tax rate follows reconciliation groups effective tax ratein millions chf groups average expected tax rate tax effect unrecognised tax losses nontaxable incomenondeductible expenses impairment financial assets differences continuing businesses exceptional items effective tax rate profit income tax profit income tax tax taxes rate tax taxes rate continuing businesses exceptional items effective tax rate amortisation goodwill major legal cases changes group organisation continuing businesses exceptional income bond conversion redemption continuing businesses effective tax rate discontinuing businesses changes group organisation discontinuing businesses groups effective tax rate annual report notes roche group consolidated financial statements income tax assets liabilitiesin millions chf current income taxes current income tax assets current income tax liabilities net current income tax asset liability deferred income taxes deferred income tax assets deferred income tax liabilities net deferred income tax asset liability deferred income tax assets recognised tax loss carry forwards extent realisation related tax benefit probable group unrecognised tax losses including valuation allowances million swiss francs million swiss francs million swiss francs expire within four years million swiss francs expire within six years remaining million swiss francs losses expire fifteen years deferred income tax liabilities established withholding tax taxes would payable unremitted earnings certain foreign subsidiaries amounts currently regarded permanently reinvested unremitted earnings totalled billion swiss francs december billion swiss francs deferred income tax assets liabilities deferred income tax charges credits attributable following items deferred income taxes movements recognised net assets liabilitiesin millions chf property plant equipment restructuring temporary intangible assets provisions differences total net deferred income tax asset liability beginning year charged credited income statement charged credited equity acquisition igen disposal consumer health otc business currency translation effects net deferred income tax asset liability end year net deferred income tax asset liability beginning year charged credited income statement charged credited equity disetronic disposal vitamins fine chemicals business currency translation effects net deferred income tax asset liability end year annual report notes roche group consolidated financial statements property plant equipment property plant equipment movements carrying value assetsin millions chf buildings land machinery construction improve land ments equipment progress total total net book value beginning year disetronic disposal consumer health otc business disposal vitamins fine chemicals business additions disposals transfers depreciation charge impairment charge currency translation effects end year december cost accumulated depreciation net book value decrease property plant equipment million swiss francs disposal otc business consists assets transferred business million swiss francs impairment charge million swiss francs see note finance leases december capitalised cost property plant equipment finance leases amounts million swiss francs million swiss francs net book value assets amounts million swiss francs million swiss francs finance leases present value future minimum lease paymentsin millions chf within one year one five years five years total present value minimum lease payments group companies party number finance leases significant entered genentech respect manufacturing facility vacaville california certain buildings south sanfrancisco site upon lease expiry genentech may either purchase property predetermined amount sell property third party renew lease property sold third party amount lower amount financed lessor genentech agreed residual value guarantee pay lessor agreed percentage amount financed lessor genentech also required maintain financial covenants form certain predefined financial ratios limited amount debt assume carrying value lease obligations million us dollars million swiss francs annual report notes roche group consolidated financial statements genentech leasesin millions usd approximate maximum initial fair value residual property lease expiry value guarantee vacaville november south san francisco june total operating leases total operating lease rental expense million swiss francs million swiss francs operating leases future minimum payments noncancellable leases millions chf within one year one five years five years total minimum payments group companies party number operating leases mainly plant machinery including motor vehicles certain shortterm property rentals arrangements impose significant restrictions group capital commitments group capital commitments purchase construction property plant equipment totalling billion swiss francs billion swiss francs addition december genentech entered master lease agreement lease property south san francisco genentechs aggregate lease payments estimated approximately million us dollars goodwill goodwill movements carrying value assetsin millions chf net book value beginning year igen acquisition disetronic acquisition disposal consumer health otc business amortisation charge impairment charge currency translation effects end year december cost accumulated amortisation net book value genentech acquisition corange acquisition chugai acquisition disetronic acquisition igen acquisition others total annual report notes roche group consolidated financial statements goodwill arising investments associated companies classified part investments associated companies see note effective january group implement ifrs business combinations amongst matters new standard requires amortisation goodwill cease date implementation goodwill continue tested impairment standard requires prospective application standard applied goodwill amortisation expenses million swiss francs would recorded additional impairment would necessary intangible assets intangible assets movements carrying value assetsin millions chf patents licences trademarks intangible assets acquisition related total total net book value beginning year igen acquisition disetronic acquisition disposal consumer health otc business additions disposals amortisation charge impairment charge igen litigation currency translation effects end year december cost accumulated amortisation net book value remaining useful life genentech acquisition years corange acquisition years chugai acquisition years disetronic acquisition years igen acquisition years kytril years others various total majority groups intangible assets result acquisitions made group patents licenses trademarks intangible assets recorded fair value acquisition accounting subsequently amortised useful lives kytril intangible assets arise purchase group global rights kytril granisetron smithkline beecham december group currently internally generated intangible assets development criteria recognition asset met associated companies groups investments associated companies accounted using equity method goodwillarising investments associated companies classified part investments associated companies annual report notes roche group consolidated financial statements investments associated companiesin millions chf share net income balance sheet value basilea pharmaceutica switzerland investments associated companies total investments associated companies basilea pharmaceutica group owns noncontrolling interest basilea pharmaceutica ltd basilea basilea swiss biotechnology company antibacterial antifungal dermatology fields groups major investments associates tripath inc antisoma additional information companies given note transactions group associated companies given note april group announced would longer continue joint development renal transplantation drug isatx isotechnika result group longer potential exercise significant influence isotechnika accordingly isotechnika longer reported associated company impairment loss million swiss francs none recorded groups investments associates joint ventures groups interests joint ventures reported financial statements using proportionate consolidation method significant joint ventures detailed bayer joint ventureas part disposal roche consumer health business see also note group sold bayer stake bayer roche llc joint venture bayer overthecounter otc field market distribute product aleve certain otc products united states joint ventures recognised income statement balance sheet amounts millions chf income statement sales expenses net income taxes balance sheet longterm assets current assets noncurrent liabilities current liabilities net assets financial longterm assets financial longterm assetsin millions chf availableforsale investments heldtomaturity investments loans receivable longterm trade receivables restricted cash total financial longterm assets prepaid employee benefits total longterm assets annual report notes roche group consolidated financial statements financial longterm assets held strategic purposes therefore classified noncurrent availableforsale investments mainly equity investments effective interest rate heldtomaturity investments loans receivable comprise loans third parties term one year restricted cash included million us dollars million swiss francs cash investments pledged genentech connection city hope litigation see note included current assets see note inventories inventories millions chf raw materials supplies work process finished goods intermediates less provision slowmoving obsolete inventory total inventories inventories held net realisable value carrying value million swiss francs million swiss francs result disposal consumer health otc business inventories decreased million swiss francs effective december see note result disposal vitamins fine chemicals business inventories decreased million swiss francs effective september see note accounts receivable accounts receivablein millions chf trade accounts receivable notes receivable less provision doubtful accounts total accounts receivable december accounts receivable include amounts denominated us dollars equivalent billion swiss francs billion swiss francs amounts denominated euros equivalent billion swiss francs billion swiss francs bad debt expense million swiss francs million swiss francs current assets current assetsin millions chf accrued interest income prepaid expenses derivative financial instruments restricted cash receivables total current assets restricted cash consists million us dollars million swiss francs cash investments pledged genentech connection city hope litigation see note included financial longterm assets see note annual report notes roche group consolidated financial statements marketable securities marketable securitiesin millions chf heldfortrading investments bonds debentures availableforsale current investments shares bonds debentures money market instruments time accounts three months total marketable securities marketable securities held fund management purposes therefore classified current primarily denominated swiss francs euros us dollars pounds sterling investments held strategic purposes classified noncurrent see note shares consist primarily readily saleable equity securities bonds debenturesin millions chf average effective contracted maturity amount interest rate within one year one five years five years total bonds debentures within one year one five years five years total bonds debentures money market instruments generally fixed interest rates ranging depending upon currency denominated contracted mature within one year december cash cash equivalents cash cash equivalentsin millions chf cash cash hand current call accounts cash equivalents time accounts maturity three months less total cash cash equivalents annual report notes roche group consolidated financial statements accounts payable accounts payablein millions chf trade accounts payable taxes payable accounts payable total accounts payable accrued current liabilities accrued current liabilitiesin millions chf deferred income accrued payroll related items interest payable derivative financial instruments accrued liabilities total accrued current liabilities provisions contingent liabilities provisions movements recognised liabilities millions chf environmental legal restructuring provisions provisions provisions total total beginning year disposal consumer health otc business vitamin case additional provisions created utilised year major legal cases additional provisions created unused amounts reversed utilised year provisions additional provisions created unused amounts reversed utilised year increase discounted amount due passage time change discount rate currency translation effects end year current portion provisions noncurrent portions provisions total provisions expected outflow resources within one year one two years two three years three years total provisions annual report notes roche group consolidated financial statements environmental legal provisions provisions include million swiss francs million swiss francs environmental matters million swiss francs million swiss francs litigation including major legal cases vitamin case provisions environmental matters cover various separate environmental issues number countries approximately half preexisting companies acquired group nature amounts timing outflows difficult predict group estimates approximately half amount provided may result cash outflows next five years significant provisions discounted legal provisions consist mainly major legal cases notably city hope medical center litigation see note vitamin case see note amounts timing uncertainties outflows discussed notes discount rates used remaining legal provisions account less balance consist number separate legal matters various group companies majority cash outflows expected occur within next one three years although dependent development various litigations significant provisions discounted major legal cases described note vitamin case described note litigation matters currently significant described carvedilol arbitrationroche diagnostics gmbh rdg smithkline beecham cork ltd sb party arbitration concerning rdgs termination carvedilol license agreement amended relating licensing comarketing carvedilol rdg submitted claim damages arbitration tribunal zurich sb submitted counterclaim asserting invalidity rdgs termination claiming damages final decision arbitration tribunal expected earliest amount provisions recorded rdg disclosed may seriously prejudice rdgs position matter applera litigation october applera corporation applera filed suit group superior court california filed notice arbitration american arbitration association superior court lawsuit arbitration demand make claims concerning interpretation enforcement contracts group applera commercialisation polymerase chain reaction pcr technology claims seek termination certain contracts declarations regarding rights obligations contracts monetary damages relief unspecified amount alleged breaches various agreements parties december group filed response arbitration proceeding day group also responded appleras complaint superior court proceeding petitioning court compel arbitration claims alleged applera stay lawsuit pending completion arbitration october court appeal state california ruled petition compel arbitration granted remanded case superior court directions grant petition first meeting arbitration take place february provisions recorded respect matters outcome determined date financial statements promega litigationin group filed suit promega corporation promega alleging patent infringement breach licence agreement relating polymerase chain reaction pcr technology may us district court northern district california decided one patents concerned unenforceable rejected breach licence claim suit regarding alleged infringement pcr patents still progress november group notified promega filed nonpublic qui tam action group us district court eastern district west virginia march complaint filed false claims act alleges us federal government overcharged purchase pcr enzyme products july us federal government notified court decision intervene promegas complaint november court ordered complaint unsealed group filed motion dismiss complaint august court dismissed complaint prejudice annual report notes roche group consolidated financial statements restructuring provisions arise planned programmes materially change scope business undertaken group manner business conducted provisions include costs necessarily entailed restructuring associated recurring activities group remaining amounts mostly respect obligations towards former employees arising pharmaceuticals division restructuring previous restructuring plans timings cash outflows reasonably certain global basis shown table significant provisions discounted provisions provisions consist mostly claims arising trade various provisions group companies fit categories timings cash outflows nature uncertain best estimates shown table provisions discounted time value money considered material case contingent liabilities operations earnings group continue time time varying degrees affected political legislative fiscal regulatory developments including relating environmental protection countries operates industries group engaged also subject physical risks various kinds nature frequency developments events covered insurance well effect future operations earnings predictable see also note respect vitamin case note respect major legal cases group entered strategic alliances various companies order gain access potential new products utilise companies help develop groups potential new products potential future payments may become due certain collaboration partners achieving certain milestones defined collaboration agreements groups best estimate future commitments payments million swiss francs million swiss francs million swiss francs noncurrent liabilities noncurrent liabilitiesin millions chf deferred income longterm liabilities total noncurrent liabilities debt debt recognised liabilitiesin millions chf debt instruments amounts due banks financial institutions capitalised lease obligations borrowings total debt reported longterm debt shortterm debt total debt annual report notes roche group consolidated financial statements debt repayment termsin millions chf within one year one two years two three years three four years four five years five years total debt lyons zero coupon us dollar exchangeable notes see reflected due first year holders notes request group purchase notes fair value debt instruments billion swiss francs billion swiss francs fair value total debt billion swiss francs billion swiss francs calculated based upon present value future cash flows instrument discounted market rate interest instruments similar credit status cash flows maturity periods pledges groups assets connection debt except noted obligation arising leases genentech secured property plant equipment net book value million swiss francs december amounts due banks financial institutions interest rates amounts primarily denominated euros average approximately repayment dates vary one four years million swiss francs million swiss francs due within one year debt instruments recognised liabilities effective interest rates debt instrumentsin millions chf effective interest rate european medium term note programme bonds due october principal million euros bonds due august principal million pounds sterling bonds due october principal million us dollars swiss franc bonds rodeo due march principal billion swiss francs us dollar bonds chameleon due july principal million us dollars billion us dollars zero coupon us dollar exchangeable notes lyons iii due may principal billion us dollars lyons iv due january principal billion us dollars lyons v due july principal billion us dollars annual report notes roche group consolidated financial statements effective interest rate japanese yen exchangeable bonds sumo due march principal billion japanese yen limited conversion preferred stock due november japanese yen convertible bonds issued chugai series chugai pharmaceutical unsecured convertible bonds due september principal amount billion japanese yen billion japanese yen total debt instruments weighted average effective interest rate unamortised discount included carrying value debt instruments millions chf swiss franc bonds us dollar bonds euro bonds sterling bonds zero coupon us dollar exchangeable notes japanese yen exchangeable bonds total unamortised discount issues new debt instruments issues new debt instruments group established european medium term note programme three issues subsequently made cash inflows issue new debt instruments millions chf european medium term note programme eurodenominated bonds issued april sterlingdenominated bonds issued august us dollardenominated bonds issued october total cash inflows new issues year repayments redemptions conversions debt instruments group converted redeemed certain debt instruments debt reduced million swiss francs total cash outflow million swiss francs net pretax gain million swiss francs resulted shown note net gain reported exceptional item due themateriality transactions described conversion redemption lyons iv us dollar exchangeable notes march group exercised option call notes redemption april original issue amount plus accrued original issue discount oid effective interest rate notes period april notes principal amount million us dollars called conversion holders remaining notes redeemed cash april total genentech shares used meet obligations result groups ownership genentech decreased group realised pretax gain million swiss francs part disposal interest genentech redemption remaining notes annual report notes roche group consolidated financial statements redemption lyons iii us dollar exchangeable notes april group exercised option call notes redemption may original issue amount plus accrued original issue discount oid effective interest rate notes notes principal amount billion us dollars redeemed cash group realised pretax loss million swiss francs early redemption notes partial redemption chameleon us dollar bonds june group announced tender offer redemption chameleon bond effective interest rate bonds tender offer expired june pricing june point bonds principal amount million us dollars representing approximately outstanding bonds tendered redemption settlement made june group realised pretax loss million swiss francs partial early redemption bonds redemption limited conversion preferred stock mandatory redemption date november group redeemed remaining instruments original issue amount plus accrued interest effective interest rate instruments instruments principal amount million us dollars redeemed cash group realise gain loss redemption instruments reassessment probable redemption date lyons v us dollar exchangeable notes effective september group reassessed likely future cash outflows instrument concluded appropriate consider first call date july probable date cash flows accordingly using effective interest rate method group recorded pretax expense million swiss francs increase debt amount reflects increase carrying value debt allow accreted value meet issue price plus accrued original issue discount oid july cash effect partial conversion series chugai pharmaceutical unsecured convertible bonds bonds face value billion japanese yen million swiss francs converted shares chugai groups percentage ownership chugai unaffected conversion group bonds convertible chugai shares mirror chugai outstanding third parties net accounting effect chugai convertible bond conversions chugai share repurchases recorded minority interests see note conversion helveticus swiss franc convertible bonds due date july remaining swiss franc convertible bonds originally issued converted nonvoting equity securities genussscheinea total nonvoting equity securities used meet conversion obligations helveticus bonds accordance terms bonds additional cash payment chf per bond made upon conversion remaining principal conversion reduced debt million swiss francs million swiss francs form nonvoting equity securities million swiss francs form cash cash outflows repayments redemptions debt instrumentsin millions chf lyons iv us dollar exchangeable notes lyons iii us dollar exchangeable notes chameleon us dollar bonds limited conversion preferred stock bullet swiss franc bonds lyons ii us dollar exchangeable notes helveticus swiss franc convertible bonds total cash outflows repayments redemptions year terms outstanding convertible debt instruments lyons v notes exchangeable nonvoting equity securities nes american depositary shares ads exchange ratio ness exchange adss per usd principal amount maturity notes group purchase note forcash option holder january annual report notes roche group consolidated financial statements july july purchase price per usd principal amount notes usd usd usd respectively addition notes redeemable option group whole part time july issue price plus accrued original issue discount oid notes outstanding december exchanged would require nonvoting equity securities meet obligation sumo bond jpy par value exchangeable nonvoting equity securities roche holding ltd bonds redeemable maturity issue price plus accrued original issue discount oid bonds outstanding december exchanged would require nonvoting equity securities meet obligation series chugai pharmaceutical unsecured convertible bonds bond jpy par value convertible shares chugai conversion option bondholder may made time due date september bonds redeemable maturity issue price bonds outstanding december converted would require chugai shares exactly meet obligation groups percentage ownership chugai would affected conversion group bonds convertible chugai shares mirror chugai outstanding third parties derivative financial instruments appropriate circumstances group uses derivative financial instruments part risk management trading strategies discussed note derivative financial instruments carried fair value methods used determining fair value described note derivative financial instrumentsin millions chf assets liabilities foreign currency derivatives forward exchange contracts swaps interest rate derivatives swaps derivatives total derivative financial instruments hedge accounting groups accounting policy hedge accounting described note requires qualify hedge accounting hedging relationship must meet several strict conditions documentation probability occurrence hedge effectiveness reliability measurement described note group financial risk management policies cover foreign exchange risk interest rate risk market risk credit risk liquidity risk deemed appropriate certain risks altered use derivatives many transactions considered hedges economic terms required conditions met relationship qualify hedge accounting case hedging instrument hedged item reported independently hedging relationship means derivatives reported fair value changes fair value included financial income group generally limits use hedge accounting certain significant transactions consequently december group fair value hedges cash flow hedges hedges net investment foreign entity meet strict requirements qualify hedge accounting apart described annual report notes roche group consolidated financial statements group hedged fixed term debt instruments interest rate swaps december instruments designated qualify fair value hedges recorded balance sheet fair value million swiss francs genentech nonus dollar cash flows future royalty income development expenses expected next one five years hedge part transaction exposure genentech enters derivative financial instruments options forward contracts genentech equity investments various biotechnology companies subject greater risk market fluctuation stock market general manage part exposure genentech enters derivative financial instruments zero cost collars forward contracts december instruments designated qualify hedge accounting recorded balance sheet fair value million swiss francs matters also described genentech 's annual report quarterly sec filings movements fair value reserve designated cash flow hedges included note equity share capital december share capital roche holding ltd groups parent company consists shares nominal value swiss franc preceding year shares bearer shares group maintain register shareholders based information supplied group shareholders group pooled voting rights owns issued shares described note based information supplied group novartis international ltd basel affiliates participation issued shares nonvoting equity securitiesgenussscheine december nonvoting equity securities issue preceding year swiss company law nonvoting equity securities nominal value part share capital issued contribution would shown asset balance sheet roche holding ltd nonvoting equity security confers rights shares participate net profit remaining proceeds liquidation following repayment nominal value shares participation certificates accordance law articles incorporation roche holding ltd company entitled times exchange nonvoting equity securities shares participation certificates dividends april shareholders approved distribution dividend swiss francs per share non voting equity security swiss francs respect business year distribution holders outstanding shares nonvoting equity securities totalled million swiss francs million swiss francs recorded retained earnings board proposed dividends business year swiss francs per share nonvoting equity security subject approval annual general meeting february equity instruments following redemption lyons ii exchangeable notes april see note light restructuring groups treasury operations debt financing group carried comprehensive review arrangements whereby covers potential conversion obligations may arise convertible debt instruments group refinanced various instruments cover potential obligations deliver nonvoting equity securities group sold nonvoting equity securities previously held series transactions addition nonvoting equity securities utilised disetronic transaction see note utilised conversion helveticus bonds see note group also agreed counterparties restructure previous arrangements used writtenshort put options purchasedlong call options strike price combined effect forward purchase december arrangements closed addition thegroup purchased various counterparties low exercise price options lepos give group right purchase nonvoting equity securities low strike price annual report notes roche group consolidated financial statements equity instrumentsin equivalent number nonvoting equity securities december december nonvoting equity securities low exercise price options forward purchases derivative instruments total nonvoting equity instruments equity instruments recorded within equity original cost acquisition details equity instruments held december shown table fair values disclosed information purposes equity instruments supplementary information equivalent number nonvoting strike price fair value equity securities maturity chf millions chf nonvoting equity securities na na low exercise price options feb nov derivative instruments roche option plan feb feb options feb apr total nonvoting equity securities low exercise price options mainly held potential conversion obligations may arise groups convertible debt instruments see note groups potential obligations employees roche option plan see note covered call options exercisable time maturity group also holds residual number options purchased use groups previous option compensation scheme closed see note net cash inflow transactions equity instruments million swiss francs net cash outflow million swiss francs additionally net cash outflow million swiss francs refinancing instruments covering convertible debt obligations group holds none shares earnings per share nonvoting equity security basic earnings per share nonvoting equity security calculation basic earnings per share nonvoting equity security number shares non voting equity securities reduced weighted average number nonvoting equity securities held group period annual report notes roche group consolidated financial statements basic earnings per share nonvoting equity security continuing businesses group net income millions chf number shares millions number nonvoting equity securities millions weighted average number nonvoting equity securities held millions weighted average number shares nonvoting equity securities issue used calculate basic earnings per share millions basic earnings per share nonvoting equity security chf diluted earnings per share nonvoting equity security calculation diluted earnings per share nonvoting equity security net income weighted average number shares nonvoting equity securities outstanding adjusted effects dilutive potential shares nonvoting equity securities potential dilutive effects arise convertible debt instruments employee stock option plans outstanding convertible debt instruments converted would lead reduction interest expense increase number shares may net dilutive effect earnings per share exercise outstanding vested employee stock options would dilutive effect exercise outstanding vested genentech employee stock options would dilutive effect net income genentech positive diluted earnings per share nonvoting equity security shows potential impacts dilutive effects earnings per share figures diluted earnings per share nonvoting equity security continuing businesses group net income millions chf elimination interest expense net tax convertible debt instruments dilutive millions chf increase minority share group net income net tax assuming outstanding genentech stock options exercised millions chf net income used calculate diluted earnings per share millions chf weighted average number shares nonvoting equity securities issue millions adjustment assumed conversion convertible debt instruments dilutive millions weighted average number shares nonvoting equity securities issue used calculate diluted earnings per share millions diluted earnings per share nonvoting equity security chf annual report notes roche group consolidated financial statements fair value reserves fair value reserves movement recognised amountsin millions chf fair value fair value reserve reserve available qualifying equity currency forsale cash flow conversion translation investments hedges options reserve total total beginning year changes fair value fair value gains losses recognised income statement fair value gains losses recognised balance sheet deferred income taxes minority interests currency translation gains losses end year included movements currency translation reserve million swiss francs relating consumer health otc business included calculation gain disposal business see note minority interests minority interests movement recognised amounts millions chf beginning year minority share group net income net tax net effect movements fair value charged credited equity conversion redemption lyons iv us dollar exchangeable notes net effect exercise genentech stock options genentech stock repurchases net effect partial conversion chugai convertible bonds chugai share repurchases chugai dividend payments currency translation effects end year genentech chugai total minority interests related parties controlling shareholders share capital roche holding ltd groups parent company consists bearer shares based information supplied shareholders group pooled voting rights comprising ms vera michalskihoffmann ms maja hoffmann mr andr hoffmann dr andreas oeri ms sabine duschmaloeri mscatherine oeri ms beatrice oeri ms maja oeri group holds shares preceding year represents issued shares figure include shares without pooled voting rights held outside group individual members group annual report notes roche group consolidated financial statements mr andr hoffmann dr andreas oeri members board directors roche holding ltd capacity receive annual remuneration thousand swiss francs addition mr hoffmann dr oeri receive thousand swiss francs thousand swiss francs respectively time expenses related membership board committees retirement annual general meeting april drfritz gerber member mentioned shareholders group also member board directors roche holding limited period april dr gerber received remuneration thousand swiss francs pension thousand swiss francs transactions group individual members shareholders group subsidiary associated companies listing major group subsidiaries associated companies included note transactions parent company subsidiaries subsidiaries eliminated consolidation transactions group associated companies millions chf income statement income sale goods supply services expenses purchase goods supply services milestone upfront payments balance sheet trade accounts receivable trade accounts payable key management personnel members board directors roche holding ltd receive annual remuneration payment time expenses related membership board committees total payments nonexecutive directors remuneration expenses million swiss francs million swiss francs payments dr franz b humer also member executive committee included figures executive committee members executive committee received total remuneration shown table remuneration members executive committeein millions chf salary bonuses total cash remuneration paid options awarded equivalent number nonvoting equity securities pension social insurance contributions paid group part roche performance share plan members executive committee awarded nonvoting equity securities fair value million swiss francs respect groups performance see also note supplementary information given within groups corporate governance disclosures pages annual report notes roche group consolidated financial statements cash flow statement cash flows operating activities cash flows operating activities derived groups primary activities described divisional review calculated indirect method adjusting groups operating profit operating income expenses cash flows example depreciation amortisation impairment order derive cash generated operations operating cash flows shown cash flow statement operating cash flows also include income taxes paid activities including example taxes paid gains conversion redemption bonds cash generated operationsin millions chf net income add back nonoperating income expense income associated companies financial income exceptional income bond conversion redemption income taxes income applicable minority interests operating profit depreciation property plant equipment amortisation goodwill amortisation intangible assets impairment longterm assets changes group organisation chugai transaction writeoff fair value adjustments inventories major legal cases expense defined benefit postemployment plans adjustments cash generated operations cash flows investing activities cash flows investing activities principally arising groups investments property plant equipment intangible assets acquisition divestment subsidiaries associated companies businesses cash flows connected groups portfolio marketable securities investments also included interest dividend payments received respect securities investments cash flows indicate groups net reinvestment operating assets cash flow effects changes group organisation well cash generated groups investments interest dividends receivedin millions chf interest received dividends received total cash flows financing activities cash flows financing activities primarily proceeds issue repayments groups equity debt instruments also include interest payments dividend payments instruments cash flows shortterm financing including finance leases also included cash flows indicate groups transactions providers equity debt financing cash flows shortterm borrowings shown net movement consist large number transactions short maturity annual report notes roche group consolidated financial statements interest dividends paidin millions chf interest paid dividends paid total significant noncash transactions significant noncash investing financing transactions included conversion lyons iv notes genentech shares see note significant noncash investing financing transactions included nonvoting equity securities used disetronic acquisition see note dsm shares acquired disposal vitamins fine chemicals business see note nonvoting equity securities used conversion helveticus bonds see note subsequent events significant events balance sheet date annual report notes roche group consolidated financial statements subsidiaries associated companies listed companies share capital equity interest country company city mill switzerland roche holding ltd basel chf stock exchange zurich valor share valor genussscheine isin share ch isin genussscheine ch market capitalisation chf mill basilea pharmaceutica ltd basel chf stock exchange zurich nasdaq biotech valor isin ch market capitalisation chf mill usa genentech inc south san francisco usd stock exchange new york incorporated delaware isin us market capitalisation usd mill tripath imaging inc burlington usd stock exchange nasdaq nm isin us market capitalisation usd mill japan chugai pharmaceutical co ltd tokyo jpy stock exchange tokyo isin jp market capitalisation jpy mill great britain antisoma plc london gbp stock exchange london isin gb market capitalisation gbp mill nonlisted companies share capital equity interest country company city mill argentina productos roche sa qumica e industrial buenos aires ars australia roche diagnostics australia pty limited castle hill aud roche products pty limited dee aud syntex australia limited north sydney aud austria roche austria gmbh vienna eur roche diagnostics gmbh vienna eur bangladesh roche bangladesh ltd dhaka bdt belgium nv roche sa brussels eur roche diagnostics belgium sa brussels eur bermuda canadian pharmholding ltd hamilton gbp corange international ltd hamilton usd corange ltd hamilton usd roche capital management ltd hamilton usd roche capital transactions limited hamilton usd roche financial investments ltd hamilton usd roche financial services ltd hamilton usd roche healthcare limited hamilton usd roche interfinance ltd hamilton usd roche international finance bermuda ltd hamilton usd roche international ltd hamilton usd roche intertrade ltd hamilton usd roche services holdings ltd hamilton usd syntex pharmaceuticals international ltd hamilton usd brazil produtos roche qumicos e farmacuticos saso paulo brl roche diagnostics brasil ltda paulo brl bulgaria roche bulgaria eood sofia bgn canada chempharm limited toronto cad hoffmannla roche limited toronto cad sapac corporation ltd st john usd annual report notes roche group consolidated financial statements share capital equity interest country company city mill chile productos farmoqumicos roche ltda santiago de chile clp china roche diagnostics hong kong limited hong kong hkd roche diagnostics shanghai limited shanghai usd roche hong kong limited hong kong hkd roche rd center china ltd shanghai usd shanghai roche pharmaceuticals limited shanghai usd colombia productos roche sa bogot cop costa rica productos roche sa san jos usd roche servicios sa san jos usd czech republic roche sro prague czk denmark roche hvidovre dkk dominican productos roche dominicana sa santo domingo dop republic ecuador roche ecuador sa quito usd egypt roche egypt sae giza egp ropharm limited giza egp el salvador productos roche el salvador sa san salvador usd finland roche oy espoo eur france hoffmannla roche france sas neuillysurseine eur roche diagnostics sa meylan eur roche sa neuillysurseine eur germany disetronic medical systems gmbh sulzbach eur galenus mannheim gmbh mannheim eur hestia health care gmbh mannheim eur hoffmannla roche aktiengesellschaft grenzachwyhlen eur roche deutschland holding gmbh grenzachwyhlen dem roche diagnostics gmbh mannheim eur great britain roche diagnostics ltd lewes gbp roche holding uk limited welwyn garden city gbp roche products limited welwyn garden city gbp roche registration limited welwyn garden city gbp greece roche hellas sa athens eur guatemala productos roche guatemala sa guatemala gtq guernsey roche capital market international limited st peter port chf roche financial market limited st peter port chf roche international finance st peter port chf corporation limited honduras productos roche honduras sa tegucigalpa hnl hungary roche hungary ltd budapest huf india roche diagnostics india pvt ltd mumbai inr roche scientific company india mumbai inr private limited indonesia pt roche indonesia jakarta idr ireland roche ireland limited clarecastle eur roche products ireland limited dublin eur italy roche diagnostics spa milan eur roche spa milan eur japan roche diagnostics kk tokyo jpy luxembourg pharminvest sa luxembourg eur malaysia roche diagnostics malaysia sdn bhd kuala lumpur myr roche malaysia sdn bhd kuala lumpur myr annual report notes roche group consolidated financial statements share capital equity interest country company city mill mexico grupo roche syntex de mxico sa de cv mexico city mxn lakeside de mxico sa de c v mexico city mxn productos roche sa de cv mexico city mxn syntex sa de cv mexico city mxn morocco roche sa casablanca mad netherlands roche diagnostics nederland bv almere eur roche finance europe bv woerden eur roche nederland bv woerden eur roche pharmholding bv woerden eur new zealand roche diagnostics new zealand pty ltd auckland nzd roche products new zealand limited auckland nzd nicaragua productos roche nicaragua sa managua nio norway roche norge oslo nok pakistan roche pakistan ltd karachi pkr panama productos roche interamericana sa panama city usd productos roche panam sa panama city pab roche capital corporation panama city usd syntex corporation panama city usd peru productos roche qumica farmacutica sa lima pen philippines roche philippines inc makati php poland roche diagnostics polska sp z oo warsaw pln roche polska sp z oo warsaw pln portugal roche farmacutica qumica lda amadora eur roche sistemas de diagnsticos sociedade lindaavelha eur unipessoal lda puerto rico syntex puerto rico inc humacao usd russia roche moscow ltd moscow rub singapore roche diagnostics asia pacific pte ltd singapore sgd roche singapore pte ltd singapore sgd slovakia roche slovensko sro bratislava skk south africa roche products proprietary limited johannesburg zar south korea roche diagnostics korea co ltd seoul krw roche korea company ltd seoul krw spain andreu roche sa madrid eur roche diagnostics sl barcelona eur roche farma sa madrid eur syntex roche sa madrid eur sweden roche ab stockholm sek roche diagnostics scandinavia ab bromma sek switzerland disetronic handels ag burgdorf chf disetronic holding ag burgdorf chf disetronic licensing ag burgdorf chf disetronic medical systems ag burgdorf chf f hoffmannla roche ltd basel chf imib insitute medical informatics basel chf biostatistics ltd pharmexbio ltd zug chf rabbitair ltd zurichkloten chf roche diagnostics schweiz ltd rotkreuz chf roche diagnostics international ltd steinhausen chf roche finance ltd basel chf roche instrument center ltd rotkreuz chf roche kapitalmarkt ag basel chf roche pharma switzerland ltd reinach chf syntex corporation basel chf taiwan roche diagnostics ltd taipei twd roche products ltd taipei twd annual report notes roche group consolidated financial statements share capital equity interest country company city mill thailand roche diagnostics thailand limited bangkok thb roche thailand limited bangkok thb turkey roche diagnostik sistemleri ticaret istanbul try roche mstahzarlari sanayi anonim sirketi istanbul try uruguay roche international ltd montevideo uyu sapac corporation ltd montevideo uyu usa american roche international inc little falls cad disetronic medical systems inc st paul usd hoffmannla roche inc nutley usd igen international inc wilmington usd roche carolina inc florence usd roche colorado corporation boulder usd roche diagnostics corporation indianapolis usd roche holdings inc wilmington usd roche laboratories inc nutley usd roche molecular systems inc pleasanton usd roche palo alto llc palo alto usd venezuela productos roche sa caracas veb share capital less local currency units annual report report group auditors report group auditors general meeting roche holding ltd basel group auditors audited consolidated financial statements income statement balance sheet statement changes equity cash flow statement notes pages roche holding ltd year ended december prior year corresponding figures audited group auditors consolidated financial statements responsibility board directors responsibility express opinion consolidated financial statements based audit confirm meet legal requirements concerning professional qualification independence audit conducted accordance auditing standards promulgated swiss profession international standards auditing isa require audit planned performed obtain reasonable assurance whether consolidated financial statements free material misstatement examined test basis evidence supporting amounts disclosures consolidated financial statements also assessed accounting principles used significant estimates made overall consolidated financial statement presentation believe audit provides reasonable basis opinion opinion consolidated financial statements give true fair view financial position results operations cash flows accordance international financial reporting standards ifrs comply swiss law recommend consolidated financial statements submitted approved kpmg klynveld peat marwick goerdeler sa john morris erik fj willems basel january annual report multiyear overview statistics reported b statement income millions chf sales ebitda operating profit net income research development balance sheet millions chf longterm assets current assets total assets equity minority interests noncurrent liabilities current liabilities additions property plant equipment personnel number employees end year key ratios net income sales net income equity research development sales current ratio equity minority interests total assets sales per employee thousands chf data shares nonvoting equity securities number shares number nonvoting equity securities genussscheine total shares nonvoting equity securities total dividend millions chf earnings per share nonvoting equity security diluted chf dividend per share nonvoting equity security chf cash warrants addition dividend adjusted chf cash warrants addition dividend unadjusted chf information table stated reported changes accounting policy arising changes international financial reporting standards stock split applied retrospectively addition normal dividend shareholders approved share nonvoting equity security special ro centenary warrant worth chf date issue holders option cash equivalent chf b net income related key ratios shown special charges million swiss francs net tax incurred following corange acquisition include corange respect balance sheet data annual report multiyear overview e e c c c warrants held final exercise date dividend include special dividend relating spinoff fragrances flavours division e dividend proposed board directors annual report multiyear overview sales division millions chf pharmaceuticals diagnostics consumer health otc vitamins fine chemicals fragrances flavours total sales geographical area millions chf switzerland european union rest europe europe north america latin america japan rest asia asia africa australia oceania total additions property plant equipment division millions chf pharmaceuticals diagnostics consumer health otc vitamins fine chemicals fragrances flavours others total additions property plant equipment geographical area millions chf switzerland european union rest europe europe north america latin america japan rest asia asia africa australia oceania total annual report supplementary net income eps information groups basic diluted earnings per share information given note consolidated financial statements pages supplementary eps information given net income exceptional items also core net income additionally excludes amortisation intangible assets related impacts income taxes minority interests net income exceptional items core net income millions chf net income continuing businesses goodwill amortisation income tax minority interests major legal cases income tax minority interests changes group organisation income tax minority interests exceptional financial income income tax minority interests net income exceptional items continuing businesses amortisation intangible assets income tax minority interests core net income eps exceptional items core eps eps exceptional items core eps net income millions chf elimination interest expense net tax convertible debt instruments dilutive increase minority share group net income net tax assuming outstanding genentech stock options exercised net income used calculate diluted earnings per share per share information millions shares nonvoting equity securities weighted average number shares nonvoting equity securities issue adjustment assumed conversion convertible debt instruments dilutive weighted average number shares nonvoting equity securities issue used calculate diluted earnings per share earnings per share dilutedchf annual report roche securities share price performance chf roche share adjusted swiss market index rebased nonvoting equity security genussschein price performance chf roche nonvoting equity security adjusted swiss market index rebased american depositary receipt adr price performance usd roche adr adjusted sp index rebased two roche american depositary receipts adrs equivalent one nonvoting equity security genussscheinadrs traded united states overthecounter market since july information tables restated stock split roche shares nonvoting equity securities genussscheine effective may change ratio adrs effective january annual report roche securities number shares nonvoting equity securitiesa number shares nominal value chf chf number nonvoting equity securities genussscheine nominal value total data per share nonvoting equity security chf net income equity dividend c stock price shareb high low yearend stock price nonvoting equity security genussscheinb high low yearend market capitalisation millions chf yearend key ratios yearend net income equity dividend yield shares dividend yield nonvoting equity securities genussscheinein priceearnings shares priceearnings nonvoting equity securities genussscheine nonvoting equity security genussschein confers rights shares participate available earnings remaining proceeds liquidation following repayment nominal value shares participation certificate capital shares nonvoting equity securities listed swiss exchange roche holding ltd restrictions ownership shares nonvoting equity securities b stock price data reflect daily closing prices c dividend proposed board directors ticker symbols share nonvoting equity security american depositary receipt reuters ros rogvx rhhbypk bloomberg ro sw rog vx rhhby us swx swiss exchange ro rog annual report roche holding ltd basel financial statements income statement millions chf income income participations interest income loans group companies interest investment income gain disposal participations income group companies income total income expenses financial expenses administration expenses loss disposal participations depreciation participations expenses total expenses profit year taxes taxes net profit year annual report financial statements balance sheet december millions chf longterm assets participations longterm loans group companies total longterm assets current assets shortterm loans group companies accounts receivable group companies accounts receivable marketable securities liquid funds total current assets total assets equity share capital nonvoting equity securities genussscheine pm pm general legal reserve free reserve special reserve available earnings balance brought forward previous year net profit year total equity noncurrent liabilities provisions loans group companies total noncurrent liabilities current liabilities accounts payable group companies liabilities total current liabilities total liabilities total equity liabilities pm pro memoria nonvoting equity securities nominal value annual report notes financial statements general financial statements roche holding ltd basel prepared accordance provisions swiss law valuation methods translation foreign currencies balance sheet assets liabilities disclosed net realisable values exceptions rule participations shown acquisition values less appropriate writedowns marketable securities shown lower cost market value unrealised foreign currency gains balance sheet items deferred expenses income well foreign currency transactions translated exchange rates ruling relevant transaction dates details specific items taxes tax charge includes corporate income capital taxes withholding taxes stamp duty equity movement recognised amounts millions chf general share legal free special available total capital reserve reserve reserve earnings equity january net income dividends paid transfer free reserve december net income dividends paid transfer free reserve december net income dividends paid transfer free reserve december share capital previous year share capital amounts million swiss francs share capital consists bearer shares nominal value swiss franc included equity non voting equity securities genussscheine part share capital confer voting rights however nonvoting equity security genussscheindoes confer rights one shares participate available earnings remaining proceeds liquidation following repayment share capital guarantees within framework european medium term note emtn programme company issued guarantees favour group companies amounting million swiss francs previous year million swiss francs time preparing balance sheet risks arising contingent liabilities discernible annual report notes financial statements convertibles options reference made notes consolidated financial statements equity instruments reference made notes consolidated financial statements pledged assets assets total book value million swiss francs previous year million swiss francs pledged security companys commitments participations major participations listed pages important shareholders shares company bearer shares reason company keep register shareholders following figures based information shareholders shareholder validation check annual general meeting april information available company previous year shares shareholders group pooled voting rights comprising ms vera michalskihoffmann ms maja hoffmann mr andr hoffmann dr andreas oeri ms sabine duschmaloeri mscatherine oeri ms beatrice oeri ms maja oeria previous year shares participation novartis international ltd basel including affiliates thereofb information supplied shareholders figure shares include shares without pooled voting rights held outside group individual members group b figures december supplied novartis international ltd basel annual report appropriation available earnings proposals general meeting chf available earnings net profit year balance brought forward previous year total available earnings appropriation available earnings distribution ordinary dividend chf gross per share nonvoting equity security genussschein chf last year transfer free reserve total appropriation available earnings carried forward account annual report report statutory auditors general meeting roche holding ltd basel statutory auditors audited accounting records financial statements income statement balance sheet notes pages roche holding ltd year ended december theprior year corresponding figures audited auditors financial statements responsibility board directors responsibility express opinion financial statements based audit confirm meet legal requirements concerning professional qualification independence audit conducted accordance auditing standards promulgated swiss profession require audit planned performed obtain reasonable assurance whether financial statements free material misstatement examined test basis evidence supporting amounts disclosures financial statements also assessed accounting principles used significant estimates made overall financial statement presentation believe audit provides reasonable basis opinion opinion accounting records financial statements proposed appropriation available earnings comply swiss law companys articles incorporation recommend financial statements submitted approved kpmg klynveld peat marwick goerdeler sa john morris erik fj willems basel january annual report sales manufacturing overview switzerland costa rica argentina czech republic australia denmark austria dominican republic bangladesh ecuador belgium egypt bermuda el salvador brazil finland canada france chile germany china great britain colombia greece annual report roche global market presence roche global market presence research development services financing toll manufacturing third parties guatemala morocco russia guernsey netherlands singapore honduras new zealand south africa hungary nicaragua south korea india norway spain indonesia pakistan sweden ireland panama taiwan italy peru thailand japan philippines turkey luxembourg poland uruguay malaysia portugal usa mexico puerto rico venezuela annual report published cautionary statement regarding forward fhoffmannla roche ltd looking statements baselswitzerland annual report contains certain forwardlook tel ing statements forwardlooking statements fax may identified words believes expects anticipates projects intends media office seeks estimates future similar expressions corporate communications discussion among things strategy baselswitzerland goals plans intentions various factors may tel cause actual results differ materially future fax reflected forwardlooking statements contained annual report among others investor relations pricing product initiatives competitors baselswitzerland legislative regulatory developments tel economic conditions delay inability fax obtaining regulatory approvals bringing prod ucts market fluctuations currency world wide web exchange rates general financial market condi httpwwwrochecom tions uncertainties discovery develop ment marketing ofnew products new uses order publications existing products increased government pric tel ing pressures interruptions production fax loss inability obtain adequate protec emailbaselwebmasterrochecom tion intellectual property rights litigation loss ofkey executives employeesand adverse publicity news coverage next annual general meeting february trademarks mentioned enjoy legal protection roche annual report published german original language english roche annual report issued f hoffmannla roche ltd basel corporate communications design wirz corporate ag zurich source associates ag zurich photos roland tnnler zurich raphael david koch zurich roche corporate photolibrary basel typesetting staufferfebel ag basel lithos lithoteam ag allschwilbasel printers birkhusergbc ag reinachbasel binding buchbinderei grollimund ag reinachbasel annual report